Your browser does not support the audio element.

In 2020, for the first time, medication abortions accounted for more than half of all abortions in the United States. Thats after the pandemic led the FDA to lift a restriction that had required doctors to dispense Mifepristone, one of the two pills used to induce abortion, in person.

The pills are approved to terminate a pregnancy that is up to 10 weeks along. The pills can be taken at home and they cause similar symptoms to spontaneous miscarriage.

If the U.S. Supreme Court overturns Roe v. Wade, which is expected this month, abortion will likely become illegal in about half of the states. But abortion pills could wind up in a legal gray area approved at the federal level by the FDA, but subject to state-level abortion bans.

And because they will remain available in neighboring states that allow abortion and through online suppliers, they offer a potential workaround for anyone who wants an abortion but doesnt have the resources to travel to a state where it is legal. In Texas, for example, the number of people ordering abortion pills from an online telemedicine service tripled after state legislators passed an abortion ban in 2021.

States are already moving to limit access to medication abortion, and the FDA has sent warning letters to some of the online telemedicine companies that have tried to develop workarounds to state-level regulations.

In Oregon, a state with no restrictions on abortion, the pills are available at a wide variety of hospitals and clinics, or through telehealth appointments. Medication abortions account for about 70% of those provided by the two Planned Parenthood affiliates in Oregon, which are responsible for more than half of all abortions statewide.

To put together this guide, we spoke with two experienced obstetrician-gynecologists, the type of doctor who typically provides prenatal care and delivers babies, about abortion pills.

Oregon Health & Science Universitys Dr. Maureen Baldwin has been part of clinical trials of telemedicine abortion where a medical provider meets with and evaluates a patient via videoconference before and during the pandemic.

Dr. Paula Bednarek is an associate professor of obstetrics and gynecology at OHSU and the medical director of Planned Parenthood Columbia-Willamette.

Both doctors are supporters of abortion rights.

Using pills to end an unwanted pregnancy, or to manage a miscarriage, is known as a medication abortion. The most effective method uses two drugs: Mifepristone and Misoprostol.

Mifepristone, originally known as RU-486, is taken first. It blocks progesterone, a hormone thats needed to continue a pregnancy.

The second medication, Misoprostol, is generally taken at least 24 hours later. It starts contractions and prompts the body to expel the pregnancy. (This medication is also sometimes used to induce labor at the end of a full-term pregnancy.)

Each medication has been used individually to induce abortion, but they are most effective when taken in combination at nine weeks or less. When a pregnancy is less than seven weeks along, there is a less than 1% chance of a pregnancy continuing after following the two-step protocol, according to Baldwins research. After seven weeks, the chance of a pregnancy continuing rises incrementally. In the tenth week of pregnancy, the chance of a pregnancy continuing is about 8%.

Medication abortion is used to end pregnancies that are less than 10 weeks, or 70 days along, counted from the last day of the most recent period.

Its also an option that can help manage pregnancy loss when the process of miscarrying has started but hasnt completed naturally.

Medication abortion can be used at any point after getting a positive pregnancy test, around 4 weeks.

In a clinical or hospital setting under medical supervision, medication abortion can sometimes be used to end a pregnancy that is further than 10 weeks along. There is a higher risk of significant and dangerous bleeding after 10 weeks.

There are relatively few risk factors that make the procedure unsafe for people seeking an abortion in early pregnancy. Medication abortion is not used for people with a known allergy to Mifepristone, certain bleeding disorders, suspected ectopic pregnancy, chronic adrenal failure, or people on chronic steroid therapy. It is also not used when someone has gotten pregnant with an IUD in place.

Yes, but only if those people are physically located in Oregon for their appointment or telehealth appointment.

That is part of how all telemedicine is regulated. Providers have to be licensed in the state where the patient is located and follow the laws of the state where the patient is located.

The patient also needs an Oregon mailing address if they plan to receive pills by mail.

In the United States, getting Mifepristone requires a consultation and prescription from a doctor or health professional.

In Oregon, that can happen in person, or through telemedicine over the phone or online.

First, a doctor evaluates the patient to confirm how far along they are in pregnancy and to determine if there are any reasons the procedure might not be safe for a particular patient.

Baldwin says in most cases, an ultrasound isnt necessary.

We know from a lot of research that patients who have been recording their periods are very accurate in knowing how far along they are, she said.

Patients can pick up the medication in person at a doctors office or Planned Parenthood clinic, or have the medication mailed to them. Its not yet available in retail pharmacies.

After taking the second medication, Misoprostol, the patient may feel nauseous and throw up. They will have a lot of bleeding and cramping.

The length of time it takes to pass the pregnancy tissue can vary. It can be a very fast process, 90 minutes overall. Or, the bleeding and pain can last a few days and come and go in waves.

Standard care includes a follow-up evaluation to ensure the pregnancy tissue has all been passed.

At OHSU, for example, there are three options: a self-evaluation and home pregnancy test a few weeks afterward, an ultrasound in a clinic following the abortion, or blood tests for pregnancy hormone levels before and after the procedure.

Some people really want to have a visual, Baldwin said. In fact, we know that a lot of people come to emergency departments after a medication abortion for reassurance actually that the pregnancy has completed, she said.

Abortions are available at all Planned Parenthood health centers, at many private obstetrics and gynecology practices and in the Kaiser Permanente, OHSU, and Legacy Health systems.

Providence Health Services provides medical and surgical abortions for patients experiencing miscarriage, pregnancy loss, or a life-threatening emergency, along with resources to cope with the loss. Providence will not provide induced or elective abortions. Providence patients who are Oregon Health Plan members can access abortion through a different provider, regardless of the reason, by calling Oregon Health Plan client services at 1-800-273-0557.

Neither the Indian Health Service nor Veterans Affairs provide abortions, due to the Hyde Amendment, a law that restricts federal funding for abortion.

Federally Qualified Health Centers. which provide primary care to low-income, uninsured, rural and historically disadvantaged populations, also do not provide abortions, due to congressional restrictions. They do provide referral services for abortions and other options for their patients.

All of these services will continue to remain legal in Oregon unless state legislators change the laws here, which seems unlikely given the political make-up of the state government right now.

Boxes of the drug mifepristone line a shelf at the West Alabama Women's Center in Tuscaloosa, Ala., on Wednesday, March 16, 2022. The drug is one of two used together in "medication abortions." According to Planned Parenthood, mifepristone blocks progesterone, stopping a pregnancy from progressing.

Allen G. Breed / AP

Mifepristone was invented in France and was first approved by the FDA for abortion, in combination with Misoprostol, in 2000.

Misoprostol is FDA approved to treat ulcers. Its used for abortions and, at a lower dose, for labor induction. The medications uses in gynecology are included in the labeling for Mifepristone and are considered safe by the American College of Obstetricians and Gynecologists.

The FDA regulates Mifepristone more tightly than most drugs and collects more complete safety data on it. Since 2011, the FDA has added what is known as a Risk Evaluation and Mitigation Strategy (REMS) to the drug. Doctors who prescribe it have to follow some special record-keeping practices and report any cases of complications, and patients who take it have to sign a form saying theyve been informed of the risks.

In December 2021, the FDA rolled back some prior restrictions on the drug. As a result, by the end of 2022, it may be available in some retail pharmacies.

Some may prefer being able to have an abortion in the comfort of their home. Some people may feel it is less invasive, or more natural, than a surgical procedure. Medication abortion via telehealth may be easier for those who live in parts of the state without a nearby abortion provider.

It is also easier to book an appointment for a medication abortion, according to Bednarek. Surgical abortions are only available in some Planned Parenthood locations in Oregon, on specific days of the week.

There is a similar safety profile for medication abortion and surgical abortion for early pregnancy. Surgical abortions do have advantages. They are more predictable and over more quickly, with less bleeding.

If somebody wants to have sedation and be asleep and have it be less pain and be over with more quickly and not have to experience the process of the abortion, that is an option with surgical abortion, Baldwin said.

A persons pain level can vary based on their prior experience with pregnancy, birth, or pregnancy loss. It can also vary based on how far along a pregnancy is. For some people, the cramping may be as painful as labor contractions. For others, it is more like bad period cramping.

Ibuprofen, a heating pad, and a warm bath or shower can be effective in helping patients manage the most significant cramping, which typically lasts in the 4-6 hour range.

People should not take aspirin. It can cause them to bleed more.

Some patients may want stronger pain medication.

We talk with patients and we provide whatever pain medicine they feel that they need, which might include a prescription for a narcotic pain medicine, but most often over-the-counter medicines are really effective, said Bednarek.

There can be a physical and emotional recovery process afterward, that can vary with the circumstances that surround a persons choice to get abortion care. Some feel relief. Others feel sadness. Many feel lots of things all at once.

Abortions, including medication abortions, are generally safe procedures.

In 2018, the National Academies of Sciences, Engineering, and Medicine convened an expert committee to review the practice of abortion in the United States. The committees final report reads: Legal abortionswhether by medication, aspiration, D&E, or inductionare safe. Serious complications are rare and occur far less frequently than during childbirth. Safety is enhanced when the abortion is performed as early in pregnancy as possible.

(Aspiration is a procedure that involves suctioning out pregnancy tissue. The term D&E stands for dilation and evacuation, and involves dilating the cervix and surgically removing pregnancy tissue.)

During a minority of medication abortions, less than 5%, complications arise.

The most common complication is that it doesnt work. In that case, a follow-up surgical abortion is required.

Rarely, in less than 1% of cases, medication abortions can cause more serious and even fatal complications. These include prolonged heavy bleeding, infections and sepsis, and ruptured ectopic pregnancies.

In an extremely small number of cases, medication abortion has been linked to infection with clostridum sordellii, a particularly dangerous type of bacterial infection thats also a rare complication of miscarriage and childbirth. It can trigger toxic shock syndrome and can be hard to diagnose because patients may have an infection without a fever.

According to the Mifepristone label, people should contact their provider or seek help if they have:

In the US, medication abortion has an associated mortality rate of less than 1 in 100,000, according to the Kaiser Family Foundation. The mortality rate associated with giving birth is 23.8 deaths per 100,000 live births, according to the CDC. In the United States, there are more deaths annually due to accidental Tylenol overdoses than from all types of abortion.

Thats also safe, according to research conducted during the pandemic.

A study published in 2021 looked at more than 50,000 patients in the United Kingdom who received medication abortions. One group had received the pills at an in-person clinic visit that included an ultrasound. The other group received the pills by mail, after a telehealth consultation.

The study found no evidence of worse outcomes linked to telemedicine abortion. It found telemedicine abortion had significant advantages. Patients had shorter waiting times and there was a 40% increase in the number of abortions provided at 6 weeks gestation or less.

The FDA warns against purchasing Mifepristone and Misoprostol outside of the American medical system.

For someone living in Oregon, often. Medication abortion is covered by the Oregon Health Plan and by many private insurance plans. It is not covered for tribal members who get care through the Indian Health Service, nor to veterans who get care through the VA, due to the Hyde Amendment.

It is not covered for people on a Providence Health Plan.

If everyone in the United States has access to abortion pills and quality information on how to use them, and when to seek help, it could reduce some of the medical risks associated with a return to illegal abortions. In short, the pills may make illegal or self-managed abortions safer than they were in 1973.

In terms of what options are for self-managed abortions were a world away from where we were, Bednarek said.

There is some evidence, for example, that the availability of Misoprostol in some Caribbean, Latin American, and African countries has reduced maternal mortality from unsafe abortions.

Self-managed abortion may carry significant legal risks. In some states with laws that oppose abortion, prosecutors have filed homicide charges against people who tried to end their pregnancies outside the medical system. And in Pennsylvania, a mother who bought abortion pills online for her daughter was sentenced to 18 months in prison for violating state abortion regulations.

Bednarek says in states where Planned Parenthood cannot legally provide medication abortion, it can provide information to anyone who has obtained pills outside the regular health care system.

If patients call us with questions and need help, we are here to support them at any point through their process, she said.

Anyone who has started the process outside the health care system and is experiencing complications or warning signs can also get help at Planned Parenthood.

We can still do an ultrasound, we can help them with additional medications or an aspiration procedure if thats part of whats needed, we can evaluate them for ectopic pregnancy, Bednarek said. Patients should not feel worried that they will be judged or turned in or something like that.

See the rest here:
Medication abortions are easy to access in Oregon, but how do they work? - Oregon Public Broadcasting

Recommendation and review posted by Bethany Smith

For effective, long-lasting birth control, its hard to beat an IUD, a.k.a. intrauterine device, for foolproof pregnancy protection. An IUD can live in your uterus for up to 12 years, protecting you from unwanted pregnancy with more than 99% effectiveness. IUDs are safe and reliable, but is there a catch? We talked to OB-GYNs about how this semi-mysterious method of birth control works, and what you should be aware of before having one put in your body.

Credit: Reviewed / Getty Images / flocu

This T-shaped contraceptive method is inserted directly into the uterus so there's no need for timely phone reminders or painful injections.

Made of plastic and/or copper, IUDs are semi-flexible, T-shaped devices no bigger than the size of a small sugar packet. Theyre inserted by a gynecologist and have two short strings attached at the bottom, which makes removal less arduous when it comes time to do so. The FDA currently approves of five devices: Paragard, Mirena, Kyleena, Liletta, and Skyla.

There are two types of IUDs you can get: hormonal and non-hormonal. Mirena, Kyleena, Liletta, and Skyla are hormonal IUDs, while Paragard is hormone-free. Both hormonal and non-hormonal IUDs prevent pregnancy by damaging or killing sperm, making it more difficult for them to swim to and fertilize an egg.

Its important to note that IUDs dont protect against sexually transmitted infections (STIs), so you should still use condoms to protect yourself and your partner during intercourse.

Depending on the type you get, IUDs prevent pregnancy in one of two ways. The hormone-free Paragard IUD uses a small amount of copperapproximately 176 mg, per the FDAto weaken sperm by creating an inhospitable environment in your uterus that isnt sperm-friendly. Conversely, hormone-based Mirena, Kyleena, Liletta, and Skyla use progestin, an artificial hormone similar to progesterone, to thicken cervical mucus and even prevent ovulation, or the releasing of an egg from the ovary. Thicker mucus can block or trap sperm to prevent it from fertilizing an egg, and preventing ovulation means theres no egg to fertilize to begin with.

Though Paragard, Mirena, and Liletta start working right away, youll want to wait at least 24 hours before having sex or inserting objects, such as tampons or sex toys, into your body. The same applies with Skyla and Kyleena, which take one week to become fully effective, unless insertion happens during the week following your period. (So remember to use a backup method of birth control for those seven days.) The copper Paragard can also be used as emergency contraception and is 99% effective at preventing unwanted pregnancy if implanted up to five days after having unprotected sex.

The benefits of either type of IUD are that they are long-acting, reversible contraception and can be left in place for several years, says Dr. Carolyn Ross, MD, OB-GYN, and Stix medical advisor.

Credit: Reviewed / Getty Images / Lalocracio

Both non-hormonal and hormonal IUDs contribute to pregnancy prevention within the uterus.

Hormonal IUDs are smaller than the copper option, making insertion somewhat easier. Its typical to experience spotting for a few months after insertion, but after that, a hormonal IUD often makes periods lighter and less painful, and can even stop you from getting your period altogether, which could be beneficial for those who suffer from heavy, painful periods.

Like other methods of hormone-based birth control, hormonal IUD side effects may include acne, headaches, irregular bleeding, mood changes, and cramping. And because the progestin is localized to your uterus, any positive side effects, such as clearer skin or reduced unwanted hair growth, from previous birth control methods like the pill may subside.

If youve had negative experiences with the pill or other types of hormonal contraception, the appeal of a copper IUD is almost undeniable. Effective for 12 years, it lasts the longesta great bang for your pregnancy-prevention buck.

However, the extended protection might be overkill for anyone in the 40-plus crowd, and a progestin-emitting option may be more cost-effective for anyone (depending on your insurance), so chat with your OB-GYN about your family-planning options.

One of the biggest cons, though? Your monthly flow may be heavier and steadier. Copper IUDs can cause heavy periods and cramping, especially in the first six months. Though that typically improves with timeand periods may eventually end entirely while the IUD is in placethis can be a deal-breaker for new IUD users. If the intense side effects from a copper IUD dont subside after six months, call your doctor to talk about your options.

Yes, but the chances are extremely slimless than 1%, to be exact. And because its a set it and forget it method of birth control, theres no risk of using it incorrectlyno more having to set alarms to remember to take your birth control pill at the same time every day.

An IUD remains effective from three to 12 years, depending on the makeup or dose of hormone used. With an effectiveness of 12 years, Paragard lasts the longest, while Mirena and Liletta work for seven, Kyleena for five, and Skyla for three.

While even three years might seem like an eternity for anyone who suspects their desire to get pregnant may change, you dont need to leave yours in the entire time to make it worth your while. And your ability to conceive returns almost immediately with removal.

Depending on your insurance or lack thereof, the price of an IUD can range anywhere from $0 to $1,300, but usually there is no cost, thanks to the Affordable Care Acts birth control mandate. Most insurance plans cover all forms of birth control, including IUDs, but they may only cover certain brands, so check with your insurance provider to see what options are available. If you dont have insurance, you wont automatically pay over a grandvisiting a Title X clinic such as Planned Parenthood can help reduce the cost.

Credit: Reviewed / Getty Images / Uffoow

Normal sensations after IUD insertion are cramping, slight lower back pain, and even some light bleeding.

Unlike most other forms of birth control, you must get your IUD placed and removed at your doctors office. During the insertion, your doctor or nurse will use a speculum to open your cervix and place the IUD in your uterus. You may receive medicine to help soften your cervix and be advised to take over-the-counter painkillers like ibuprofen ahead of your appointment. The process usually takes less than five minutes, and patients typically report cramping during the procedure, the severity of which can vary from person to person, according to Dr. Ross.

If youre nervous about feeling lightheaded or dizzy after insertion, ask your partner or a trusted friend or family member to come with you so they may drive you home. Its normal to experience cramping throughout the day following an IUD insertiona good heating pad and some ibuprofen can help alleviate this.

After getting your IUD placed, youll be able to feel the strings poking out of your cervix into the top of your vagina with your fingers. Your doctor may recommend feeling forbut not pulling onthose strings once a month to make sure the IUD hasnt slipped or moved. This is a rare occurrence, but can happen during the first three months following insertion.

The removal process is significantly easier. Your doctor will use forceps to clasp and pull on the IUD strings. As the IUD comes up against the cervix, the arms of the T-shaped device will fold up, and the IUD will slide out through the cervix and vagina. Patients may experience spotting after getting an IUD removed, and it may take a few months for your period to return to normalbut because your ability to get pregnant can return immediately, be aware that youll need to use another form of birth control right away if youre not quite ready to conceive.

If you get pregnant with an IUD, youre at higher risk for having an ectopic pregnancy, in which the fertilized egg attaches outside of the uterus, typically in the fallopian tube. However, because IUDs are so effective at preventing pregnancy, those with IUDs are at less risk for this than those who are sexually active but dont use contraception.

Infection is possible from the insertion procedure, but rare. Its also possible your body will reject your IUD and expel itthis is why its important to check on those IUD strings to make sure they havent moved. Expulsion is more likely if youve never been pregnant, have heavy or prolonged periods, have previously expelled an IUD, are younger than 20, or had your IUD inserted immediately after childbirth.

Additionally, because the IUDs strings extend into the vagina, it can be risky to use most menstrual cups for period protection, as they can create a suction against the cervix, which could dislodge the IUD when the cup is removed. (Disc-style cups, like the Nixit, can be used instead, as they dont suction in place.) The strings can also make sex uncomfortable for your partner initially, as theyre stiff after insertion but soften over time. If that doesnt happen, schedule a follow-up visit with your doctor, who can trim the strings to make intercourse more comfortable.

The product experts at Reviewed have all your shopping needs covered. Follow Reviewed on Facebook, Twitter, Instagram, TikTok, or Flipboard for the latest deals, product reviews, and more.

Prices were accurate at the time this article was published but may change over time.

Original post:
How does an IUD work and how long does it last? - Reviewed

Recommendation and review posted by Bethany Smith

When thinking about mens health, many people tend to think about heart disease or ailments that that affect men as they age, such as an enlarged prostate or prostate cancer.

But men can suffer from various health issues at any age. June is Mens Health Month and the focus is to encourage men to be proactive about healthy lifestyle choices and seek medical attention early.

When you look at men and their relationship with physicians, men dont go to the doctor enough. They wait until something is wrong, says Dr. David Thiel, a Mayo Clinic urologist.

The problem with waiting is that a man might be missing the early signs of another health issue. For example, erectile dysfunction is a common ailment that brings men to see their doctor. But Dr. Thiel notes that it may be the first indicator of a more serious health condition.

Its important for men to know, especially younger men who have erectile dysfunction, that this condition is often associated with other medical conditions such as heart disease, diabetes, blood pressure problems and the like. So erectile dysfunction may not just be erectile dysfunction, explains Dr. Thiel.

Women do a much better job of annual care for surveillance with things such as cervical cancer, breast cancer and so on. We want men to know its important for them to do the same. Its important to seek care not only when something is wrong, but also for preventive care.

While concerns about cancer bring many men to the doctor, heart attack, stroke, diabetes, and hypertension are much more prevalent in the population than prostate cancer, says Dr. Thiel.

Men should have a PSA, or prostate-specific antigen, check if not every year, every two to three years, to establish a baseline for evaluation of possibly clinically significant prostate cancer in the future. But, really, starting at age 40, men should have an annual physical, and have their blood pressure, cholesterol and blood sugar checked.

Based on age, family history and any symptoms, additional blood work to check hormone levels and a colonoscopy may be recommended. Due to rising rates of colon cancer, in 2021, the U.S. Preventive Services Task Force changed its recommendations to initiate colorectal cancer screening beginning at age 45 for both men and women.

Dr. Thiel also suggests an annual flu vaccine and making sure other immunizations are up to date.

Its important for men to look at the overall big picture of their health to ensure a longer, better quality of life, he says.

Being proactive about healthy lifestyle choices and seeking medical attention early can help men maintain their health.

Read the original here:
Men's Wellness: Being proactive, annual care key to maintaining health - LimaOhio.com

Recommendation and review posted by Bethany Smith

Larger, deeper root systems can help store more carbon in the soil, because if a plant dies and parts of it are deep underground, the carbon in those pieces is less likely to make its way back into the air quickly. Roots arent the only possible storage option, Ringeisen says. Modified plants could also be used to make bio-oil or biochar, which can be pumped deep underground for storage.

Optimizing plants for carbon removal will be challenging, says Daniel Voytas, a genetic engineer at the University of Minnesota and a member of IGIs scientific advisory board.

Many of the traits that researchers want to alter in plants are influenced by multiple genes, which can make precise editing difficult, he says. And while some plants, like tobacco and rice, have been so extensively studied that researchers broadly understand how to tweak them, the genetics of others are less well understood.

Most of the IGIs initial research on photosynthesis and root systems will focus on rice, Ringeisen says. At the same time, the institute will also work on developing better gene-editing techniques for sorghum, a staple crop that has been particularly tough for researchers to crack. The team hopes to eventually understand and potentially alter soil microbes as well.

This is not easy, but were embracing the complexity, Ringeisen says. Ultimately, he hopes that when it comes to climate change, plants and microbes and agriculture can actually be part of the solution, rather than part of the problem.

View original post here:
This CRISPR pioneer wants to capture more carbon with crops - MIT Technology Review

Recommendation and review posted by Bethany Smith

Shares of CRISPR Therapeutics fell more than 11% on Monday as investors reacted negatively to the endorsement of a rival beta-thalassemia gene therapy developed by bluebird bio.

Last week, the U.S. Food and Drug Administrations Cell, Tissue and Gene Therapies Advisory Committee unanimously supported bluebirds beti-cel, a one-time gene therapy for patients with transfusion-dependent beta-thalassemia, a rare, inherited blood disorder caused by a genetic defect in hemoglobin.

Beti-cel, also known as betibeglogene autotemcel, is marketed in Europe as Zynteglo. Late-stage clinical data showed that 89% of patients who could be evaluated achieved transfusion independence following treatment with beti-cel, and safety data has been positive. The FDA is expected to give its final verdict on beti-cel by Aug. 19.

One day after the advisory committee endorsed beti-cel for beta-thalassemia, CRISPR Therapeutics and its partner Vertex Pharmaceuticalsreleasedpositive data for their gene therapy candidate, exa-cel. Exa-cel is a CRISPR-Cas9-based gene editing therapy for both transfusion-dependent beta-thalassemia (TDT) and severe sickle cell disease (SCD).

Data shared by the companies showed that 42 of 44 patients with TDT who received exa-cel have remained transfusion free for up to 37.2 months. The two patients who were not transfusion free had 75% and 89% reductions in transfusion volume, the companies said.

In SCD, the data was also positive. All 31 patients with sickle cell disease that is characterized by recurrent vaso-occlusive crises (VOCs) were free of the events following treatment with exa-cel. Data showed the patients had a duration of up to 32.3 months, CRISPR and Vertex reported, which expanded their partnership in this space last year.

Carmen Bozie, head of global medicines development and medical affairs at Vertex, touted the data. Bozie noted that of the 75 patients treated with exa-cel, 33 have one year or more of follow-up after infusion with the gene therapy. The data demonstrate the potential of exa-cel as a one-time functional cure for patients with transfusion-dependent beta-thalassemia or severe sickle cell disease, she said in a statement.

While bluebirds beti-cel was largely free of serious adverse events, Vertex and CRISPR reported that two of the 44 TDT patients experienced an SAE. One of the patients experienced three serious events that were connected to exa-cel, as well as busulfan, which was administered along with the gene therapy. That patient experienced hemophagocytic lymphohistiocytosis (HLH), a life-threatening condition related to excessive immune response, as well as acute respiratory distress syndrome and headache. The other patient experienced idiopathic pneumonia syndrome that was considered related to both exa-cel and busulfan, the companies said.

Among the 31 patients with SCD, there were no SAEs considered related to exa-cel.

CRISPR and Vertex are not alone in chasing bluebird bio to market with a gene therapy for beta-thalassemia. Editas Medicine is also developing its own gene therapy for the debilitating disease.

Earlier this year, Editas wonRare Pediatric Disease designationfor its experimental beta-thalassemia gene therapy, EDIT-301. The therapeutic is designed to edit the HBG1/2 promoter to disrupt the binding site of BCL11a and ameliorate disease symptoms.

In May, EDIT-301 won Orphan Drug designation for the treatment of beta-thalassemia and SCD. Editas expects to initiate a Phase I/II study of EDIT-301 in patients with transfusion-dependent beta-thalassemia later this year.

Here is the original post:
CRISPR Tx Shares Fall as bluebird's Gene Therapy Soars - BioSpace

Recommendation and review posted by Bethany Smith

John Leonard, CEO of Intellia Therapeutics, has just finished an hour-long meeting in the company's Cambridge headquarters, which is a five-minute jog from the MIT campus. He stretches his arms, interlocks his fingers and rests them at the back of his head. For a moment, the 64-year-old is relaxed. But he immediately reanimates when explaining the science of DNA editing, excitedly using markers, a duster and whatever else he can find to make his point. I've used my wife's necklaces on occasion, he says. Leonard suggests imagining human DNA as a necklace made of 3 billion beads and four different colors. The challenge is how do you find 20 beads to the exclusion of everything else, he adds. The beads hes referring to are genes, sections of DNA which give cells the instructions they need to do their work.

John Leonard

Many companies use Crispr, a revolutionary method of precisely editing DNA which was the basis for the Nobel Prize in Chemistry in 2020, to snip disease-causing genes in the lab and then inject the fixed cells back into patients. Intellia does that too. But it is its other gene editing platform which has grabbed eyeballs at Wall Street. The $3.6 billion market cap company has figured out how to use Cripsr outside of the lab, inside a living human. Their work could have major implications in developing new drugs for genetic diseases that currently only have limited or no treatments. Intellia is the first to do in vivo genome editing in a systemic manner. I think that's the real differentiating factor for me, says Jack Allen, senior analyst at Baird Equity Research.

Despite the novelty of its gene editing technology, the company is facing significant headwinds. In the last 12-months it lost $277 million on revenues of $33 million. Revenues have been declining on a quarterly basis since 2020 while losses have been widening. The company has raised a total of $1.8 billion, including $115 million when it when public in 2016, and they still have $1 billion in cash on hand. But at present burn rates, that will only last a couple of years. Intellia does has one promising drug in early-stage clinical trials, but around 90% of treatments at this stage fail to reach the market. And then there is the patent battle over their core technology.

It sounds pretty grim, and Intellias stock has taken a beating. Since the start of the year, Intellia shares are 62% down compared to 23% for the Nasdaq and 24% for Nasdaqs biotech index. Still Intellia has at least one ace in the hole: The man who runs the company is no stranger to these challenges. Leonard, a medical doctor by training, has a track record which few others can point to in this industry. In 1992, Leonard joined Abbott where his team's research earned an FDA approval for HIV drug, Norvir and Kaletra, which helped curtail the AIDS epidemic in the nineties. And in 2013 he joined Abbvie, Abbotts biopharmaceutical spin off, where he was instrumental in the development of Humira, which had sales of $21 billion last year, making it one of the worlds best-selling drugs.

I worked on Humira for 13 years, Leonard says. I learned a lot of principles about an organization. What makes it work? What makes it not work sometimes.

His experiences of getting these blockbuster drugs from lab bench to the market could help turn Intellias liver drug NTLA-2001, which it is co-developing along with Regeneron Pharmaceuticals, into a success. The drug is an injectable gene editing therapy for the treatment of ATTR amyloidosis a rare genetic condition of the liver which impacts 1 in 100,000 Americans and kills around 850 of them a year.

The market for treating this disease was $585 million in 2019. But more people probably have the disease and are not being properly diagnosed. Better diagnoses could lead this to become a $14.1 billion market within 7 years, according to a report by London-based consultancy GlobalData. There are currently three FDA approved drugs which slow the progress of the disease, but none of them are permanent cures and patients often end up still needing liver transplants. In February, Intellia released early data from its clinical trials showing a sustained, positive effect on participants, without worrying side effects.

Despite promising data, Intellias road ahead isnt bump free. The company licenses the Crispr technology which it uses to perform in vivo gene edits from the University of California, the University of Vienna, and pathogen researcher Emmanuel Charpentier (collectively known as the CVC group). University of California biochemist Jennifer Doudna who won the Nobel along with Charpentier for discovering the Crispr editing system is an Intellia cofounder, although she has limited day-to-day responsibilities.

Those patents held by the CVC group are where the legal trouble comes in. Patents obtained by the CVC group are at odds with others owned by the Broad Institute, the powerhouse medical research center started by the late billionaire Eli Broad and affiliated with both Harvard and MIT. That spawned a legal battle, starting in 2016, with tens of millions of dollars in royalties at stake, about who was first to invent the Crispr gene editing tool used in human and plant cells. In over 80 countries including China, Japan and the 27 nations in the European Union, it has been held that Doudnas CVC group invented it first. But in the U.S., a recent verdict by the Patent Trial and Appeal Board (PTAB) ruled in favor of the Broad Institute. The CVC group is appealing.

Fortunately, this ruling does not impact the development of CRISPR in anyway, says Doudna. Investors are continuing to put money into the space, she adds.

Of course, even if Intellia loses in court, they will still be able to license the technology. Anyone who does not have a license from the Broad Institute and that is conducting work with [Crispr] is probably going to have to get one at some point. I would imagine that that would include Intellia, says Jacob Sherkow, a professor of law at the University of Illinois.

"Fortunately, this (PTAB) ruling does not impact the development of CRISPR in anyway. Investors are continuing to put money into the space."

Leonard is looking beyond the intellectual property battle. His focus currently is on expanding the companys development pipeline to include treatments for many more diseases, such as hereditary angioedema, hemophilia, blood and ovarian cancers. But first, Leonard will have to solve the patent mess and raise more money. Given the promise of Intellias technology, he is optimistic.

I think when people make judgments about where to put their cash to work, they look at the real possibility of [drug development] programs making it to the marketplace. We're definitely in that category, Leonard says. So we think we're well positioned to continue the funding of the company as we go forward.

He is even more optimistic about the future of Crispr-based drugs, which have the potential to relegate a whole host deadly diseases to the history books. In the coming years we will be limited not by technology but by imagination.

Here is the original post:
Gene Genies: Inside The Revolutionary Biotech That Can Edit DNA Inside Living Humans - Forbes

Recommendation and review posted by Bethany Smith

The Global CRISPR/Cas9 MarketReport provides in-depth analysis of emerging trends, market drivers, development opportunities, and market constraints that may have an impact on the market dynamics of the industry. Each market sector is examined in depth in the Market Research Intellect, including goods, applications, and a competitive analysis.

The report was created using three different reconnaissance systems. The first step requires conducting extensive primary and secondary research on a wide range of topics. Approvals, evaluations, and discoveries based on accurate data obtained by industry specialists are the next steps. The research derives an overall estimate of the market size using top-down methodologies. Finally, the research evaluates the market for a number of sections and subparts using information triangulation and market separation techniques.

The primary objective of the report is to educate business owners and assist them in making an astute investment in the market. The study highlights regional and sub-regional insights with corresponding factual and statistical analysis. The report includes first-hand, the latest data, which is obtained from the company website, annual reports, industry-recommended journals, and paid resources. The CRISPR/Cas9 report will facilitate business owners to comprehend the current trend of the market and make profitable decisions.

Market Leaders Profiled:

Report Analysis & Segments:

The CRISPR/Cas9 is segmented as per the type of product, application, and geography. All of the segments of the CRISPR/Cas9 are carefully analyzed based on their market share, CAGR, value and volume growth, and other important factors. We have also provided Porters Five Forces and PESTLE analysis for a deeper study of the CRISPR/Cas9.The report also constitutes recent development undertaken by key players in the market which includes new product launches, partnerships, mergers, acquisitions, and other latest developments.

Based on Product Type CRISPR/Cas9 is segmented into

Based on the Application CRISPR/Cas9 is segmented into

The report provides insights on the following pointers:

1 Market Penetration: Comprehensive information on the product portfolios of the top players in the CRISPR/Cas9.

2 Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

3 Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market.

4 Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

5 Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CRISPR/Cas9.

Schedule a Consultation Call With Our Analysts / Industry Experts to Find a Solution For Your Business @ https://www.marketresearchintellect.com/ask-for-discount/?rid=379235

Various Analyses Covered:

Regional assessment of the CRISPR/Cas9 has been carried out over six key regions which include North America, Asia-pacific, Europe, Latin America, Middle East, and Africa. Moreover, the report also delivers deep insights on the ongoing research & development activities, revenue, innovative services, the actual status of demand and supply, and pricing strategy. In addition to this, this report also delivers details on consumption figures, export/import supply, and gross margin by region. In short, this report provides a valuable source of guidance and clear direction for the marketer and the part interested in the market.

North America(United States, Canada)Asia Pacific(China, Japan, India, South Korea, Australia, Indonesia, Others)Europe(Germany, France, United Kingdom, Italy, Spain, Russia, Others)Latin America(Brazil, Mexico, Others) The Middle East and Africa

Frequently Asked Questions:

About Us:Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:Mr. Steven FernandesMarket Research IntellectNew Jersey (USA)Tel: +1-650-781-4080

Email:[emailprotected]

Website: https://www.marketresearchintellect.com/

See the original post:
CRISPR/Cas9 Market Size And Forecast to 2028 |Caribou Biosciences, Integrated DNA Technologies (IDT), CRISPR Therapeutics, Merck, Mirus Bio Indian...

Recommendation and review posted by Bethany Smith

A good bargain stock isn't just an inexpensive one. There are plenty of stocks out there that are $10 or less or have a low price-to-earnings ratio (P/E). Both of those metrics can be deceiving, however. A lot of low-priced stocks deserve to be where they are, and many stocks with low P/Es are downtrodden because their futures aren't that bright.

The best bargains are the ones that will be good stocks to have and hold for the long term, yet are priced to sell right now. CRISPR Therapeutics (CRSP 8.29%), Microsoft (MSFT 1.09%), and Garmin (GRMN 0.74%) all have great long-term prospects and, for the moment, all are priced at a discount, down more than 20% this year.

Following the rest of the market, CRISPR Therapeutics is down nearly 20% this year as it trades at around $60. That leaves CRISPR with a P/E ratio of 15.7, under the biotech industry average of 20.3. But it's not its low P/E that's important but the potential.

CRISPR is a clinical-stage biotech company that uses the CRISPR/Cas9 gene-editing platform to create therapies to treat cancer, blood diseases, diabetes, and other diseases.

The company has a potential blockbuster, Exacel, formerly known as CTX-001, that it is developing with Vertex Pharmaceuticals. The drug is in late-stage trials for the treatment of patients with transfusion-dependent beta-thalassemia (TDT) or severe sickle cell disease (SCD), two genetic blood disorders that can cause painful episodes because of malformed blood cells that cause blockages in the bloodstream.

The drug works by editing a patient's own stem cells. It is a single-dose therapy that could significantly help the 300,000 people who are born worldwide each year with SCD and the 80,000 with TDT. CRISPR and Vertex said they anticipate regulatory filings for Exa-cel by the end of this year.

Exa-cel is only the tip of a large pipeline for CRISPR Therapeutics, which has several therapies in early-stage trials. Those trials include VCTX210 to treat type 1 diabetes, as well as three immuno-oncology therapies: CTX-110 to treat certain B-cell cancers, CTX-120 to treat multiple myeloma, and CTX-130 to treat solid tumors and blood cancers.

The company reported $178,000 in collaboration revenue in the first quarter and a loss of $179.2 million in the quarter, which deepened from the loss of $113.2 million in the same period last year. However, it is in a strong cash position, with $2.4 billion, allowing it to finance the development of its growing pipeline.

Microsoft is down more than 27% this year, trading at a new 52-week low. That drop has a lot more to do with the market's current distaste for tech stocks and very little to do with Microsoft's fundamentals, which, if you look at its 2022fiscal third-quarter earnings, remain strong.

The company reported $49.4 billion in revenue, up 18% year over year; net income of $16.7 billion, up 8% over the same period in 2021; and diluted earnings per share (EPS) of $2.22. Microsoft's cloud-based services drove much of the growth, with Office commercial products and cloud services revenue up 12%, Office consumer products, and cloud services up 11%, and dynamics products and cloud services up 22%. The company's intelligent cloud revenue was up 26%, led by 29% growth in server products and cloud services and 46% by Azure and other cloud services revenue gains.

The only cloud on the horizon is that growing inflation and a rising dollar might cut into the company's future sales. It revised its 2022 fourth-quarter guidance downward, as noted in the chart below.

Source: Chart by author. Microsoft quarterly filing.

Microsoft also said it now expects EPS to be between $2.24 and $2.32, down from between $2.28 and $2.35. A lowered estimate doesn't thrill investors, but if you look carefully, all of those numbers would represent a stronger quarter sequentially and year over year.

The company also has a dividend, unusual for a fast-growing tech company. Microsoft raised its dividend in fiscal 2021 by 11% to $0.62 per quarterly share, and last year was the 12th consecutive year the company has boosted its dividend. That dividend represents a current yield of 1% and is considered safe with a 24.4% payout ratio.

Garmin sells navigation, communication, and information devices that use the Global Position System (GPS) technology, including everything from fitness trackers to marine, automotive, and aviation GPS systems. Its stock is down more than 28% this year, sending its P/E to 17.5.

The company did well during the pandemic, as its fitness trackers became big sellers. While sales of fitness trackers are down, the company is seeing growth in other areas as it operates in five segments: fitness, outdoor, aviation, marine, and auto. The company has grown annual revenue for six consecutive years, and over the past five years, the company has increased annual revenue by 59.6%.

In the first quarter, Garmin reported revenue of $1.2 billion, up 9% year over year, though EPS was $1.09, down 4% over the same period in 2021. Despite fitness sales being down 28%, outdoor sales were up 50%, marine was up 21%, and auto rose 11% compared with the first quarter of 2021. The company said the reason earnings dropped was due to the impact of high freight costs and currency shifts, two factors that will likely moderate. Garmin has said it anticipates annual revenue of $5.5 billion, representing a growth of 8% over 2021 annual revenue.

The Swiss company raised its dividend toward the end of last year by 9% to $0.73 per quarterly share, the fifth consecutive year it has increased its dividend. That equals a yield of roughly 3%.

See original here:
3 Bargain Stocks You Can Buy Today and Hold Forever - The Motley Fool

Recommendation and review posted by Bethany Smith

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

Approval of Amendment to CRISPR Therapeutics AG 2018 Stock Option and IncentivePlan

On June 9, 2022, at the 2022 Annual General Meeting of Shareholders (the "AnnualMeeting"), the shareholders of CRISPR Therapeutics AG (the "Company") approvedthe amendment (the "Plan Amendment") to the CRISPR Therapeutics AG 2018 StockOption and Incentive Plan (the "2018 Plan") to increase the number of commonshares, par value CHF 0.03 per share ("Common Shares") reserved for issuanceunder the 2018 Plan by 1,700,000 Common Shares and to increase the number ofshares that may be issued in the form of incentive stock options by 1,700,000Common Shares. The Plan Amendment previously had been approved, subject toshareholder approval, by the Company's Board of Directors (the "Board").

The Company's officers and directors are among the persons eligible to receiveawards under the 2018 Plan, as amended, in accordance with the terms andconditions thereunder. A detailed summary of the 2018 Plan and the PlanAmendment is set forth in the Company's proxy statement for the Annual Meetingfiled with the Securities and Exchange Commission on April 25, 2022 (the "ProxyStatement") under the caption "Proposal 13: Approval of Amendment to the CRISPRTherapeutics AG 2018 Stock Option and Incentive Plan", which summary isincorporated herein by reference. That detailed summary of the 2018 Plan andPlan Amendment, and the foregoing description of the Plan Amendment, arequalified in their entirety by reference to (i) the full text of the 2018 Plan,which is filed as Exhibit 99.1 to the Company's Registration Statement on FormS-8 filed on June 1, 2018, (ii) the full text of Amendment No. 1 to the 2018Stock Option and Incentive Plan, which is attached as Appendix A to theCompany's Definitive Proxy Statement on Schedule 14A filed on April 30, 2019,(iii) the full text of Amendment No. 2 to the 2018 Stock Option and IncentivePlan, which is attached as Appendix A to the Company's Definitive ProxyStatement on Schedule 14A filed on April 24, 2020, and (iv) the full text of thePlan Amendment, a copy of which is attached as Appendix A to the ProxyStatement, and in each case, incorporated herein by reference.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

At the Annual Meeting, the Company's shareholders approved amendments to itsArticles of Association as described in the Proxy Statement. The Company'samended and restated Articles of Association become effective upon registrationin the Commercial Register in the canton of Zug, Switzerland on or about June15, 2022, subject to the approval by the Swiss Federal Commercial Authority. Acopy of the amended and restated Articles of Association is attached hereto asExhibit 3.1 and incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders

The Annual Meeting was held on June 9, 2022. Proxies were solicited pursuant tothe Proxy Statement.

At the Annual Meeting, the Company's shareholders were asked (i) to approve theSwiss statutory annual report, the consolidated financial statements and thestatutory financial statements of the Company for the year ended December 31,2021, (ii) to approve the appropriation of financial results, (iii) to dischargethe members of the Board of Directors and Executive Committee, (iv) to elect andre-elect nine members and the chairman to the Company's Board of Directors, (v)to re-elect three members of the Compensation Committee of the Board ofDirectors, (vi) to approve the compensation for the Board of Directors and theExecutive Committee, (vii) to approve the compensation paid to the Company'snamed executive officers under U.S. securities law requirements, (viii) toapprove the frequency of future shareholder advisory votes on the compensationpaid to the Company's named executive officers under U.S. securities lawrequirements, (ix) to approve an increase in the maximum size of the Board ofDirectors, (x) to approve an adjustment of the maximum number of authorizedshare capital and extend the date by which the Board of Directors may increasethe authorized share capital of the Company, (xi) to approve an adjustment ofthe conditional share capital for the conversion of bonds and similar debtinstruments, (xii) to approve an increase in the conditional share capital foremployee equity plans, (xiii) to approve the Plan Amendment, (xiv) to re-electthe independent voting rights representative, (xv) to re-elect Ernst & Young AGas the Company's statutory auditor and to re-elect Ernst & Young LLP as theCompany's independent registered public accounting

--------------------------------------------------------------------------------

firm for the year ending December 31, 2022, and (xvi) to approve the transactionof any other business that may properly come before the Annual Meeting.

The voting results reported below are final.

Proposal 1 - Approval of the Swiss Statutory Annual Report, the ConsolidatedFinancial Statements and the Statutory Financial Statements of the Company forthe Year Ended December 31, 2021

The Swiss statutory annual report, the consolidated financial statements and thestatutory financial statements of the Company for the year ended December 31,2021 were approved. The results of the vote were as follows:

Proposal 2 - Approval of the Appropriation of Financial Results

The proposal to carry forward the net income resulting from the appropriation offinancial results was approved. The results of the vote were as follows:

Proposal 3 - Discharge of the Members of the Board of Directors and ExecutiveCommittee

The discharge of the members of the Company's Board of Directors and theExecutive Committee from personal liability for their activities during the yearended December 31, 2021 was approved. The results of the vote were as follows:

--------------------------------------------------------------------------------

Proposal 4 - Election and Re-election of the Members and Chair of the Board ofDirectors

Rodger Novak, M.D., Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., BradleyBolzon, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T.Greene, Katherine A. High, M.D., and Douglas A. Treco, Ph.D. were each dulyre-elected as members of the Company's Board of Directors, Rodger Novak, M.D.was duly re-elected as the chairman of the Board of Directors, and Maria Fardis,Ph.D., was duly elected as a member of the Company's Board of Directors. Theresults of the election were as follows:

Samarth Kulkarni, Ph.D. 38,203,106 834,226 79,486 16,951,536Ali Behbahani, M.D. 27,384,666 11,649,601 82,551 16,951,536Bradley Bolzon, Ph.D. 38,760,145 275,056 81,617 16,951,536H Edward Fleming Jr., M.D. 38,817,215 217,290 82,313 16,951,536Simeon J. George, M.D. 38,646,772 386,485 83,561 16,951,536John T. Greene

Proposal 5 -Re-election of the Members of the Compensation Committee

Ali Behbahani, M.D., Simeon J. George, M.D., and John T. Greene, were each dulyre-elected as members of the Company's Compensation Committee of the Board ofDirectors. The results of the election were as follows:

Ali Behbahani, M.D. 28,225,426 10,801,138 90,254 16,951,536Simeon J. George, M.D. 37,702,802 1,324,072 89,944 16,951,536John T. Greene

Proposal 6 - Approval of the Compensation for the Board of Directors and theExecutive Committee

The total non-performance-related compensation for members of the Board ofDirectors from the Annual Meeting to the 2023 annual general meeting ofshareholders was approved on a binding basis. The results of the binding votewere as follows:

The grant of equity for members of the Board of Directors from the AnnualMeeting to the 2023 annual general meeting of shareholders was approved on abinding basis. The results of the binding vote were as follows:

--------------------------------------------------------------------------------

The total non-performance related compensation for members of the ExecutiveCommittee from July 1, 2022 to June 30, 2023 was approved on a binding basis.The results of the binding vote were as follows:

The total variable compensation for members of the Executive Committee for thecurrent year ending December 31, 2022 was approved on a binding basis. Theresults of the binding vote were as follows:

The grant of equity for members of the Executive Committee from the AnnualMeeting to the 2023 annual general meeting of shareholders was approved on abinding basis. The results of the binding vote were as follows:

Proposal 7 - Non-Binding Advisory Vote on the Compensation Paid to NamedExecutive Officers

The compensation for the named executive officers was approved on a non-bindingbasis. The results of the non-binding vote were as follows:

Proposal 8 - Non-Binding Vote on the Frequency of Advisory Votes on ExecutiveCompensation

The Company's shareholders approved, on a non-binding, advisory basis afrequency of One Year for the non-binding, advisory vote on the compensation ofthe Company's named executive officers. The Board considered these votingresults and other factors, and has determined that the Company will hold futureadvisory votes on its executive compensation on an annual basis. The results ofthe non-binding vote were as follows:

Proposal 9 - Approval of Increasing the Maximum Size of the Board of Directors

An increase in the maximum size of the Board of Directors was approved with atleast two thirds of the votes cast. The results of the vote were as follows:

--------------------------------------------------------------------------------

Proposal 10 - The Approval of an Adjustment of the Maximum Number of AuthorizedShare Capital and Extending the Date by Which the Board of Directors MayIncrease the Share Capital

The adjustment of the maximum number of authorized share capital and extensionof the date by which the Board of Directors may increase the share capital wasnot approved. The results of the election were as follows:

Proposal 11 - Approval of an Adjustment of the Conditional Share Capital for theConversion of Bonds and Similar Debt Instruments

An adjustment of the Company's conditional share capital for the conversion ofbonds and similar debt instruments was approved with at least two thirds of thevotes cast. The results of the vote were as follows:

Proposal 12 - Approval of an Adjustment of the Conditional Share Capital forEmployee Equity Plans

An adjustment of the Company's conditional share capital for employee equityplans was approved with at least two thirds of the votes cast. The results ofthe vote were as follows:

Proposal 13 - Approval of Amendment to the 2018 Stock Option and Incentive Plan

The Plan Amendment was approved. The results of the vote were as follows:

Proposal 14 - Re-election of the Independent Voting Rights Representative

Marius Meier, Attorney at Law, was duly re-elected as the independent votingrights representative. The results of the election were as follows:

--------------------------------------------------------------------------------

Proposal 15 - Re-election of the Auditors

Ernst & Young AG was duly elected as the Company's statutory auditor for theterm of office of one year, and Ernst & Young LLP was duly elected as theCompany's independent registered public accounting firm for the year endingDecember 31, 2022. The results of the election were as follows:

Proposal 16 - Transaction of Any Other Business

The transaction of any other business that properly came before the AnnualMeeting was approved. The results of the election were as follows:

--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits

# A management contract or compensatory plan or arrangement required to be filedas an exhibit pursuant to Item 15(a)(3) of Form 10-K

--------------------------------------------------------------------------------

Edgar Online, source Glimpses

See more here:
CRISPR THERAPEUTICS AG : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of...

Recommendation and review posted by Bethany Smith

TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Immatics N.V. ( IMTX, Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. ( EDIT, Editas Medicine), a leading genome editing company, today announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicines CRISPR technology and intellectual property. Editas Medicine is the exclusive licensee of Harvard and Broad Institutes Cas9 patent estates and Broad Institutes Cas12a patent estate for human medicines.

By combining Editas Medicines gene editing technology with Immatics ACTallo allogeneic, off-the-shelf adoptive cell therapy platform based on gamma-delta T cells, gamma-delta T cells can be redirected to cancer cell targets with the goal of creating cells with enhanced tumor recognition and destruction.

Engineered cell therapies have the potential to significantly impact the treatment paradigm for cancer, and our partnership with the esteemed team at Editas Medicine will provide us with further versatility and flexibility in how we engineer our ACTallo cell therapies based on a specific tumor target, said Rainer Kramer, Ph.D., Chief Business Officer, Immatics. It has always been our focus to deliver innovative science to cancer patients and this collaboration with Editas Medicine will enable us to access CRISPR technologies and apply them to our off-the-shelf gamma-delta T cell platform.

We believe that our gene editing technology can modulate and enhance the potential of cell therapies to deliver transformative medicines for the treatment of cancer. We are excited to work with the team at Immatics to develop new experimental medicines with enhanced tumor fighting abilities to help patients with cancer, said Gilmore ONeill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine.

Under the terms of the agreement, Editas Medicine will be eligible to receive an undisclosed upfront cash payment as well as additional milestone payments based on development, regulatory, and commercial milestones. In addition, Immatics will pay royalties on future net sales on any products that may result from this collaboration.

About ImmaticsImmatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

For regular updates about Immatics, visit http://www.immatics.com. You can also follow us on Instagram, Twitter and LinkedIn.

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Harvard and Broad Institutes Cas9 patent estates and Broad Institutes Cas12a patent estate for human medicines. For the latest information and scientific presentations, please visit http://www.editasmedicine.com.

Immatics Forward-Looking StatementsCertain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, expect, intend, will, estimate, anticipate, believe, predict, potential or continue, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the SEC. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.

Editas Medicine Forward-Looking Statements This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, target, should, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the expected benefits of Editas Medicines collaboration with Immatics, including any future payments it may receive under the strategic research collaboration and licensing agreement and the potential to generate medicines from the collaboration. Editas Medicine may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of Editas Medicines product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for Editas Medicines foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption Risk Factors included in Editas Medicines most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by Editas Medicines subsequent filings with the Securities and Exchange Commission, and in other filings that Editas Medicine may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent Editas Medicines views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Editas Medicine explicitly disclaims any obligation to update any forward-looking statements.

Read more:
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and...

Recommendation and review posted by Bethany Smith

Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Cmara R, Corbacioglu S. et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021. https://doi.org/10.1038/s41409-021-01227-8.

Article PubMed PubMed Central Google Scholar

D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020;26:e177e182.

Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn B-M, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:53743.

CAS PubMed Article Google Scholar

Sun Y-Q, He G-L, Chang Y-J, Xu L-P, Zhang X-H, Han W, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol. 2015;94:1699705.

CAS PubMed Article Google Scholar

de Koning C, Langenhorst J, van Kesteren C, Lindemans CA, Huitema ADR, Nierkens S, et al. Innate immune recovery predicts CD4+ T cell reconstitution after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25:81926.

PubMed Article CAS Google Scholar

Velardi E, Clave E, Arruda LCM, Benini F, Locatelli F, Toubert A. The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment. Semin Immunopathol. 2021;43:10117.

PubMed Article Google Scholar

de Koning C, Nierkens S, Boelens JJ. Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution. Blood. 2016;128:260715.

PubMed Article CAS Google Scholar

Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 1978;4:725.

CAS PubMed Google Scholar

Mendelson A, Frenette PS. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med. 2014;20:83346.

CAS PubMed PubMed Central Article Google Scholar

Lucas D, Scheiermann C, Chow A, Kunisaki Y, Bruns I, Barrick C, et al. Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nat Med. 2013;19:695703.

CAS PubMed PubMed Central Article Google Scholar

Cao X, Wu X, Frassica D, Yu B, Pang L, Xian L, et al. Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells. Proc Natl Acad Sci USA. 2011;108:160914.

CAS PubMed PubMed Central Article Google Scholar

Pronk E, Raaijmakers MHGP. The mesenchymal niche in MDS. Blood. 2019;133:10318.

CAS PubMed Article Google Scholar

Kong Y, Chang Y-J, Wang Y-Z, Chen Y-H, Han W, Wang Y, et al. Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:146573.

PubMed Article Google Scholar

Tikhonova AN, Dolgalev I, Hu H, Sivaraj KK, Hoxha E, Cuesta-Domnguez , et al. The bone marrow microenvironment at single-cell resolution. Nature. 2019;569:2228.

CAS PubMed PubMed Central Article Google Scholar

Baccin C, Al-Sabah J, Velten L, Helbling PM, Grnschlger F, Hernndez-Malmierca P, et al. Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization. Nat Cell Biol. 2020;22:3848.

CAS PubMed Article Google Scholar

Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature. 2014;508:26973.

CAS PubMed PubMed Central Article Google Scholar

Simsek T, Kocabas F, Zheng J, DeBerardinis RJ, Mahmoud AI, Olson EN, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell. 2010;7:38090.

CAS PubMed PubMed Central Article Google Scholar

Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, et al. Regulation of the HIF-1 level is essential for hematopoietic stem cells. Cell Stem Cell. 2010;7:391402.

CAS PubMed Article Google Scholar

Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature. 2013;502:63743.

CAS PubMed PubMed Central Article Google Scholar

Mndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, MacArthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466:82934.

PubMed PubMed Central Article CAS Google Scholar

Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124:40721.

CAS PubMed Article Google Scholar

Itkin T, Gur-Cohen S, Spencer JA, Schajnovitz A, Ramasamy SK, Kusumbe AP, et al. Distinct bone marrow blood vessels differentially regulate haematopoiesis. Nature. 2016;532:3238.

CAS PubMed PubMed Central Article Google Scholar

Kenswil KJG, Pisterzi P, Snchez-Duffhues G, van Dijk C, Lolli A, Knuth C, et al. Endothelium-derived stromal cells contribute to hematopoietic bone marrow niche formation. Cell Stem Cell. 2021;28:65370.

CAS PubMed Article Google Scholar

Kenswil KJG, Jaramillo AC, Ping Z, Chen S, Hoogenboezem RM, Mylona MA, et al. Characterization of endothelial cells associated with hematopoietic niche formation in humans identifies IL-33 as an anabolic factor. Cell Rep. 2018;22:66678.

CAS PubMed Article Google Scholar

Renders S, Svendsen AF, Panten J, Rama N, Maryanovich M, Sommerkamp P, et al. Niche derived netrin-1 regulates hematopoietic stem cell dormancy via its receptor neogenin-1. Nat Commun. 2021;12:115.

Article CAS Google Scholar

Xu C, Gao X, Wei Q, Nakahara F, Zimmerman SE, Mar J, et al. Stem cell factor is selectively secreted by arterial endothelial cells in bone marrow. Nat Commun. 2018;9:113.

Article CAS Google Scholar

Ludin A, Gur-Cohen S, Golan K, Kaufmann KB, Itkin T, Medaglia C, et al. Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment. Antioxid Redox Signal. 2014;21:160519.

CAS PubMed PubMed Central Article Google Scholar

Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481:45762.

CAS PubMed PubMed Central Article Google Scholar

Hooper AT, Butler JM, Nolan DJ, Kranz A, Iida K, Kobayashi M, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell. 2009;4:26374.

CAS PubMed PubMed Central Article Google Scholar

Kopp H-G, Avecilla ST, Hooper AT, Shmelkov SV, Ramos CA, Zhang F, et al. Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. Blood. 2005;106:50513.

CAS PubMed PubMed Central Article Google Scholar

Poulos MG, Guo P, Kofler NM, Pinho S, Gutkin MC, Tikhonova A, et al. Endothelial jagged-1 is necessary for homeostatic and regenerative hematopoiesis. Cell Rep. 2013;4:102234.

CAS PubMed PubMed Central Article Google Scholar

Guo P, Poulos MG, Palikuqi B, Badwe CR, Lis R, Kunar B, et al. Endothelial jagged-2 sustains hematopoietic stem and progenitor reconstitution after myelosuppression. J Clin Investig. 2017;127:424256.

PubMed PubMed Central Article Google Scholar

Chen Q, Liu Y, Jeong HW, Stehling M, Dinh VV, Zhou B, et al. Apelin+ endothelial niche cells control hematopoiesis and mediate vascular regeneration after myeloablative injury. Cell Stem Cell. 2019;25:768.e6.

CAS PubMed PubMed Central Article Google Scholar

Hildebrandt GC, Chao N. Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. Br J Haematol. 2020;190:50819.

PubMed PubMed Central Article Google Scholar

Poulos MG, Ramalingam P, Gutkin MC, Llanos P, Gilleran K, Rabbany SY, et al. Endothelial transplantation rejuvenates aged hematopoietic stem cell function. J Clin Investig. 2017;127:416378.

PubMed PubMed Central Article Google Scholar

Kim MM, Schlussel L, Zhao L, Himburg HA. Dickkopf-1 treatment stimulates hematopoietic regenerative function in infused endothelial progenitor cells. Radiat Res. 2019;192:5362.

CAS PubMed PubMed Central Article Google Scholar

Ju W, Lu W, Ding L, Bao Y, Hong F, Chen Y, et al. PEDF promotes the repair of bone marrow endothelial cell injury and accelerates hematopoietic reconstruction after bone marrow transplantation. J Biomed Sci. 2020;27:113.

Article CAS Google Scholar

Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: Protective effect of defibrotide. Blood. 2002;100:33440.

CAS PubMed Article Google Scholar

Kong Y, Wang Y, Zhang YY, Shi MM, Mo XD, Sun YQ, et al. Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Adv. 2019;3:130317.

CAS PubMed PubMed Central Article Google Scholar

Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21:101924.

CAS PubMed Article Google Scholar

Tormin A, Li O, Brune JC, Walsh S, Schtz B, Ehinger M, et al. CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood. 2011;117:506777.

CAS PubMed PubMed Central Article Google Scholar

Asada N, Kunisaki Y, Pierce H, Wang Z, Fernandez NF, Birbrair A, et al. Differential cytokine contributions of perivascular haematopoietic stem cell niches. Nat Cell Biol. 2017;19:21423.

CAS PubMed PubMed Central Article Google Scholar

Garca-Castro J, Balas A, Ramrez M, Prez-Martnez A, Madero L, Gonzlez-Vicent M, et al. Mesenchymal stem cells are of recipient origin in pediatric transplantations using umbilical cord blood, peripheral blood, or bone marrow. J Pediatr Hematol/Oncol. 2007;29:38892.

Article Google Scholar

Rieger K, Marinets O, Fietz T, Krper S, Sommer D, Mcke C, et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp Hematol. 2005;33:60511.

CAS PubMed Article Google Scholar

Nicolay NH, Perez RL, Saffrich R, Huber PE. Radio-resistant mesenchymal stem cells: Mechanisms of resistance and potential implications for the clinic. Oncotarget. 2015;6:1936680.

PubMed PubMed Central Article Google Scholar

Alessio N, Del Gaudio S, Capasso S, Di Bernardo G, Cappabianca S, Cipollaro M, et al. Low dose radiation induced senescence of human mesenchymal stromal cells and impaired the autophagy process. Oncotarget. 2015;6:815566.

PubMed Article Google Scholar

Lange SS, Takata K, Wood RD. DNA polymerases and cancer. Nat Rev Cancer. 2011;11:96110.

CAS PubMed PubMed Central Article Google Scholar

Sugrue T, Lowndes NF, Ceredig R. Mesenchymal stromal cells: radioresistant members of the bone marrow. Immunol Cell Biol. 2013;91:511.

CAS PubMed Article Google Scholar

Preciado S, Muntin S, Rico A, Prez-Romasanta LA, Ramos TL, Ortega R, et al. Mesenchymal stromal cell irradiation interferes with the adipogenic/osteogenic differentiation balance and improves their hematopoietic-supporting ability. Biol Blood Marrow Transplant. 2018;24:44351.

PubMed Article Google Scholar

Nicolay NH, Rhle A, Perez RL, Trinh T, Sisombath S, Weber KJ, et al. Mesenchymal stem cells exhibit resistance to topoisomerase inhibition. Cancer Lett. 2016;374:7584.

CAS PubMed Article Google Scholar

Poloni A, Leoni P, Buscemi L, Balducci F, Pasquini R, Masia MC, et al. Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia. 2006;20:32935.

Excerpt from:
The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation | Bone Marrow Transplantation -...

Recommendation and review posted by Bethany Smith

Bacterial culture and growth conditions

A multidrug-resistant clinical strain of V. cholerae stored in the collection of the Bacteriology Department of Tarbiat Modares University, Tehran, Iran, was used. The strain was resistant to tetracycline, ciprofloxacin, chloramphenicol, cotrimoxazole, and trimethoprim. The bacterial culture was performed in 1mL brain heart infusion (BHI) broth (Merck, Germany) at 37C until reaching the log phase. The bacterial suspension concentration was determined by measuring the absorbance at 540nm and comparing it with the standard 0.5 McFarland optical density (OD). According to the growth curve, the bacterial suspension with an OD of 1:0 (~108CFU/mL) was used21.

Bone marrow-derived mesenchymal stem cells (BM-MSCs) and Caco-2 cells were purchased from the Iranian Biological Resource Center and Pasteur Institute of Iran, respectively. BM-MSCs were confirmed by assaying the differentiation of the cells into osteoblasts and adipocytes using an immunohistochemistry (IHC) assay. BM-MSCs were also characterized using the flow cytometry method for CD34, CD45, CD44, and CD73 markers18.

BM-MSCs were cultured in lowglucose Dulbecco's modified Eagles medium (DMEM) (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, USA) and 1% penicillin/streptomycin (Gibco, USA) at 37C in a humidified atmosphere containing 5% CO2. The medium was replaced after every 2days. A total of 5105 cells were seeded in a T75 flask (SPL, Korea) containing 15mL of DMEM supplemented with 10% FBS. When the confluency of the cells was near 90% at passage 2, the medium was replaced with serum-free DMEM. Subsequently, MSC CM was collected and centrifuged at 4000rpm for 30min and finally stored at 80C until use22. According to our previous study, chitosan nanoparticles were synthesized, characterized, and loaded with the supernatant of mesenchymal stem cells23. At all stages of this study, mesenchymal stem cell conditioned media (MSC CM; 1000g), chitosan nanoparticles incorporated with mesenchymal stem cell conditioned media (MSC CM-CS NPs; 1000g+0.05%), and chitosan nanoparticles (CS NPs; 0.05%) were used.

Vibrio cholerae cell suspensions were inoculated (1:100 dilution) into 1mL BHI broth medium containing 0.05% sucrose. The bacterial suspension was inoculated with MSC CM, MSC CM-CS NPs, and CS NPs overnight at 37C to evaluate the expression of biofilm genes. After this time, each well was washed three times with PBS, and adherent cells were harvested to evaluate the expression of biofilm-related genes. PBS and V. cholerae without exposure to the compounds were used as negative and positive controls, respectively. Each assay was performed in triplicate.

Caco-2 cells were cultured in DMEM supplemented with 10% FBS, 1% l glutamine (DNA Biotech, Iran), and 1% penicillin/streptomycin and incubated at 37C with 5% CO2. The culture medium was changed every two days, and when the confluency reached 80%, the cells were passaged. Since cells in monolayer culture with full confluency can form polarized cells while maintaining cell surface molecules, we explored cells at 85% confluency for all experiments24.

Caco-2 cell viability was estimated by the conventional MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. This was tested to evaluate the viability of Caco-2 cells after the exposure time to bacteria, MSC CM, MSC CM-CS NPs, and CS N. Briefly, 2({10}^{4}) Caco-2 cells per well were seeded into a 96-well plate and cultured for 24h at 37C. The medium was removed, and the cells were exposed to bacterial suspension (10 bacteria per epithelial cell; MOI: 10), MSC CM, MSC CM-CS NPs, and CS NPs separately for 24h. To assess cytotoxicity, a separate test was also performed for 72h. After these times, the medium was removed, and MTT solution was added for 3h at 37C. Then, the formazan crystals formed in cells were dissolved in 100L of dimethyl sulfoxide (Sigma Aldrich, USA). The resulting purple solution was measured using an ELISA reader (OD 540nm) (800 TS, BioTek, Winooski, Vermont, USA). Each assay was performed in triplicate25.

For this purpose, five groups were designed: (i) untreated Caco-2 cells (negative control); (ii) Caco-2 cells incubated with V. cholerae (MOI: 10-positive control); (iii) Caco-2 cells+V. cholerae+MSC CM; (iv) Caco-2 cells+V. cholerae+CS NPs; and (v) Caco-2 cells V. cholerae+MSC CM-CS NPs. Caco-2 cells were cultured in 96-well microplates until they reached 80% confluence. Before treatment, cells were washed three times with PBS. Then, the cells were infected with V. cholerae for 1h, and the extracellular bacteria and medium was removed and replaced with DMEM-free compounds, including 100L of MSC CM, MSC CM-CS NPs, and CS NPs, for 18h at 37C. After this time, the supernatant were removed, and then Caco-2 cells were used for total RNA extraction. Each test was performed in triplicate.

Total RNA from bacteria and Caco-2 cells was extracted using an RNA Miniprep Super Kit (Bio Basic, Canada) according to the manufacturers recommendations. The RNA was assayed by absorbance at OD260/280. Samples with a ratio of 1.82.0 were used for cDNA synthesis using Yekta Tajhiz Azma, Iran. According to the protocol, template RNA (5L), random primer (0.5L), and DEPC-treated water (7.5L) were mixed, centrifuged briefly, and incubated for 5min at 70C. Then, 5 first strand buffer (4L), dNTPs (1L), RNase 40U/L (0.5L), and M_MLV (1L) were mixed and incubated for 60min at 42C, and the reaction was terminated by heating for 5min at 70C. The cDNA samples were stored at 20C until use in the following experiment.

Conventional SYBR Green-based real-time PCR was used for target gene quantification. Real-time PCR was performed by using 10L 5 Real-time PCR Master Mix (Biomake, Houston, TX, USA), 1L of each primer (Table 1), 2L of cDNA, and 6L of distilled water in a total reaction volume of 20L in Stratagene Mx3000P real-time PCR system (Stratagene, La Jolla, CA). 16S rRNA was used as an endogenous control to normalize the expression levels of target genes of V. cholerae. Beta-actin was also utilized as an internal control to normalize the expression levels in RNA samples from Caco-2 cells. The CT of each sample was measured (CT targetCT reference). We used Caco-2 cells not treated as a calibrator, and the CT method was used to determine the difference between treated cells and the control. The fold change of gene expression level was calculated using the comparative CT (2CT).

The data were analyzed by using GraphPad Prism version 6 using one-way ANOVA and Bonferroni post hoc test. P value<0.05 was accepted as significant. The results of replications were also evaluated as the meanstandard deviation (SD).

The study was reviewed and approved by the Medical Ethics Committee of Tarbiat Modares University (Code: IR.MODARES.REC.1398.060). All methods were also carried out in accordance with the guidelines and regulations related to the committee.

See the original post here:
Effects of chitosan nanoparticles loaded with mesenchymal stem cell conditioned media on gene expression in Vibrio cholerae and Caco-2 cells |...

Recommendation and review posted by Bethany Smith

Global Cord Stem Cell Banking Marketreport aids businesses in gaining knowledge about what is already there in the market, what market looks forward to, the competitive background and steps to be followed for outdoing the rivals. Effortlessness maintained in research method and application of best tools and techniques makes this market research report an outstanding. The report is bifurcated into several attributes which include manufacturers, region, type, application, market status, market share, growth rate, future trends, market drivers, opportunities, challenges, emerging trends, risks, entry barriers, sales channels, and distributors which are again detailed in the universal A business report as required to describe the topic and provide maximum information for better decision making.

The key research methodology employed here by DBMR team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary validation. It has been assured that this business report makes available absolute knowledge and insights to the clients about the new regulatory environment which suits to their organization. The winningCord Stem Cell Banking Marketbusiness report helps clients recognize new opportunities and most important customers for their business growth and increased revenue.

With the resourceful use of technology, innovative applications, and expertise,Cord Stem Cell BankingMarket analysis report is built which successfully manages large and complex market data tables. The market report is produced based on the market type, organization size, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa. Not to mention, gathered market data and information is represented very well in the persuasive Cord Stem Cell Banking Market report with the help of graphs, charts or tables to simplify the flow for better user understanding. Market share analysis and key trend analysis are the two other major success factors of this influential market survey report.

Get a Sample PDF of the Cord Stem Cell Banking Market report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cord-stem-cell-banking-market

The cord stem cell banking market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 22.2% in the above-mentioned forecast period. Increase in the number of parents storing their childs cord blood drives the cord stem cell banking market.

Cord stem cells banking is defined as the storing of the cord blood cell contained in the umbilical cord and placenta of a newborn child. This cord blood contains the stem cells which can be used in future to treat disease such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, and few others.

Global Cord Stem Cell Banking MarketScenario

According to Data Bridge Market Research the market for cord stem cell banking is booming with the rising expenditure in the healthcare solutions. The increment in the novel advancement for creating good and efficient drugs to cure unmet medical challenges for the betterment of public and patients health will deliver a strategic business growth for cord stem cell banking market globally.

The rising demand of cord stem cells by pharmaceuticals enterprises has arranged an ascending array of rise in the cord stem cell banks. This significant germination will be backed by the collection placentas of new born babies after their delivery. The stem cells procured from this source are capable of regenerating advanced cells. They help in transplantation of hematopoietic stem cell, the rate of transplantation is high so thus the requirement. These inputs yields in the graphical success of cord stem cell banking market will be visible in the forthcoming period of 2019 to 2026. Few of the factors will stand in between to hinder the market growth such as high end cost of the preservation and storage of cord stem blood cells, whereas the lower rate of familiarity among the pregnant population will affect its growth.

Now the question is which are the other regions intuitive is targeting? Data Bridge Market Research has forecasted a large growth in North America due to large healthcare infrastructure and leading investment in the cord blood cells research to generate stem cells.

For more analysis on the cord stem cell banking market request for a briefing with our analystshttps://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market

Cord Stem Cell Banking MarketDevelopment and Acquisitions in 2019

In September 2019, a notable acquisition was witnessed between CBR and Natera. This merger will develop the new chances of growth in the cord stem blood banking by empowering the Nateras Evercord branch for storing and preserving cord blood. The advancement will focus upon research and development of the therapeutic outcomes, biogenetics experiment, and their commercialization among the global pharma and health sector.

Cord Stem Cell Banking MarketScope

Cord Stem Cell Banking Marketis segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of the cord stem cell banking marketis further analyzed based on maximum granularity into further segmentation. On the basis of storage type, the market is segmented into private banking, public banking. On the basis of product type, the market is bifurcated into cord blood, cord blood & cord tissue. On the basis of services type, the market is segmented into collection & transportation, processing, analysis, storage. On the basis of source, market is bifurcated into umbilical cord blood, bone marrow, peripheral blood stem, menstrual blood. On the basis of indication, the market is fragmented into cerebral palsy, thalassemia, leukemia, diabetes, autism.

Cord stem cell trading is nothing but the banking of the vinculum plasma cell enclosed in the placenta and umbilical muscle of an infant. This ligament plasma comprises the stem blocks which can be employed in the forthcoming time to tackle illnesses such as autoimmune diseases, leukemia, inherited metabolic disorders, and thalassemia and many others.

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@https://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market

Increased acceptance of stem cell therapeutics is the vital factor escalating the market growth, also rise in the new applications of stem cells indiseasetreatment, rise in the spending on the management of chronic diseases, rise in the growth in awareness about stem cell therapeutics and increase in the mergers and acquisitions by prominent players are the major factors among others driving the cord stem cell banking market. Moreover, rise in the technological advancements and modernization in the healthcare devices and risingresearch and developmentactivities in the healthcare sector will further create new opportunities for cord stem cell banking market in the forecasted period of 2021-2028.

However, high operating cost of stem cell therapeutics and lack of awareness in many developing economies are the major factors among others which will obstruct the market growth, and will further challenge the growth of cord stem cell banking market in the forecast period mentioned above.

The cord stem cell banking market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cord stem cell banking market contact Data Bridge Market Research for anAnalyst Brief, our team will help you take an informed market decision to achieve market growth

Key Market Competitors Covered in the report

CBR Systems, IncCordlifeCells4Life Group LLPCryo-Cell International, Inc.Cryo-Save AGLifecellStemCyte India Therapeutics Pvt. LtdViacordSMART CELLS PLUS.Cryoviva IndiaGlobal Cord Blood CorporationNational Cord Blood ProgramVita 34, ReeLabs Pvt. Ltd.Regrow Biosciences Pvt. Ltd.Americord Registry LLC.New York Blood CenterMaze Cord BloodAABBStem Cell CryobankNew England Cryogenic Center, Inc.

Cord Stem Cell Banking MarketScope and Market Size

The cord stem cell banking market is segmented on the basis of storage type, product type, service type, source and indication. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis ofstorage type, the cord stem cell banking market is segmented into private banks, hybrid banks and public banks.

Based onproduct type, the cord stem cell banking market is segmented into cord blood, cord blood and cord tissue.

Based on service type, the cord stem cell banking market is segmented into collection & transportation, processing, analysis and storage.

Based on source, the cord stem cell banking market is segmented into umbilical cord blood, bone marrow, peripheral blood stem and menstrual blood

The cord stem cell banking market is also segmented on the basis of role of administration into cerebral palsy, thalassemia, leukemia, diabetes and autism.

Browse the complete table of contents at Cord Stem Cell Banking Market https://www.databridgemarketresearch.com/toc/?dbmr=global-cord-stem-cell-banking-market

Cord Stem Cell Banking MarketCountry Level Analysis

The cord stem cell banking market is analysed and market size insights and trends are provided by country, storage type, product type, service type, source and indication as referenced above.

The countries covered in the cord stem cell banking market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cord stem cell banking market due to rise in the presence of major market participants in the US, ongoing approval of stem cell lines for disease treatment, and increasing awareness among citizens in this region. Asia-Pacific is the expected region in terms of growth in cord stem cell banking market due to rise in the older population along with as surge in prevalence of chronic diseases, and rising per capita healthcare expenditure in this region.

The country section of the cord stem cell banking market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The cord stem cell banking market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for cord stem cell banking market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cord stem cell banking market. The data is available for historic period 2010 to 2019.

Key Pointers Covered in the Cord Stem Cell Banking MarketIndustry Trends and Forecast

Market SizeMarket New Sales VolumesMarket Replacement Sales VolumesMarket Installed BaseMarket By BrandsMarket Procedure VolumesMarket Product Price AnalysisMarket Healthcare OutcomesMarket Cost of Care AnalysisMarket Regulatory Framework and ChangesMarket Prices and Reimbursement AnalysisMarket Shares in Different RegionsRecent Developments for Market CompetitorsMarket Upcoming ApplicationsMarket Innovators Study

Key Pointers CoveredMarket SizeMarket GrowthTop to Bottom Market AnalysisMarket SegmentedRecent Developments for Market CompetitorsRecent Market Value for Different CountriesMarket Value and OverView of this MarketCompany Profiling of Players of this Market

Why buy this report?

The report offers a comprehensive evaluation of the Global & Regional Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.The report includes an in-depth market analysis using Porters 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.The report also contains the competitive analysis using Positioning Quadrants, the analysts Proprietary competitive positioning tool.

Market highlights:Assessment of the marketPremium InsightsCompetitive LandscapeCOVID Impact AnalysisHistoric Data, Estimates and ForecastCompany ProfilesGlobal and Regional Dynamics

Key Questions Answered in the Market Report

How did the COVID-19 pandemic affect the reception of by different statistical surveying and life sciences organizations? What is the viewpoint for the effective market during the conjecture time frame? What are the key patterns affecting the effect market? How might they impact the market in short-, mid-, and long-haul length? What is the end clients insight toward? What are the key variables affecting the effect market? What will be their effect in the short-, mid-, and long-haul term? What are the key open doors regions in the effect market? What is their possible in short-, mid-, and long haul length? What are the key systems taken on by organizations in the effect market? What are the key application regions of the effect market? Which application is supposed to hold the most noteworthy development potential during the gauge time frame? What is the favored sending model for the effect? What is the development capability of different arrangement models present on the lookout? Who are the key end clients of this statistical surveying quality? What is their separate offer in the effect market? Which territorial market is supposed to hold the most noteworthy development potential in the effect market during the conjecture time frame? Which are the central members in the effect market?

Report Coverage-The report involves data triangulation based on top-down and bottom-up approaches.The report contains details on revenues, growth rate, strategies, etc.The report highlights market and technological trends, new product developments, etc.The report elucidates the data gathered from interviews with reputed stakeholders such as product managers, C-level executives, among others, operating in the market.The report also highlights the impact of COVID-19 and suggests measures and strategies to grow in the approaching years.

Top DBMR Healthcare Reports:

https://www.einpresswire.com/article/574127712/internet-of-medical-things-iomt-market-share-size-growth-revenue-technologies-top-leaders-forecast-to-2028

https://www.einpresswire.com/article/574124944/clinical-trials-market-size-share-growth-segment-trends-developing-technologies-opportunities-forecast-to-2029

https://www.einpresswire.com/article/574118495/ehealth-market-by-emerging-trends-business-strategies-technologies-revenue-to-grow-at-cagr-of-23-00-by-2029

https://www.einpresswire.com/article/574106412/u-s-psychedelic-drugs-market-is-expected-to-reach-usd-9818-68-million-by-2029-by-source-drug-application-treatment

https://www.einpresswire.com/article/574288865/aesthetic-devices-market-grow-at-a-cagr-of-10-30-and-is-expected-to-reach-usd-28-865-17-million-by-2029

https://www.einpresswire.com/article/574277868/probiotics-market-size-share-trends-business-challenges-opportunities-industry-trends-key-players-and-revenue

https://www.einnews.com/pr_news/574565434/psychedelic-drugs-market-by-source-type-drugs-application-size-share-trends-growth-regional-overview-forecast

https://www.einnews.com/amp/pr_news/574553655/europe-digital-therapeutic-dtx-market-by-product-and-service-type-application-size-share-trends-and-technology

https://www.einpresswire.com/article/574545729/pharmaceutical-logistics-market-size-share-growth-segment-trends-developing-technologies-and-top-leading-company

https://www.einpresswire.com/article/574696424/hospital-staffing-market-by-staffing-service-type-trends-growth-is-expected-to-reach-usd-56-32-billion-by-2029

https://www.einpresswire.com/article/574713353/chimeric-antigen-receptor-car-t-therapy-treatment-market-by-therapeutic-application-processes-drugs-size-share

Read the original:
Cord Stem Cell Banking Market Gross Margins, Application, Growth,Size, Share, Trends,Top Key Players with Strategies and Forecast Designer Women -...

Recommendation and review posted by Bethany Smith

REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. ( JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that its 2022 Annual Meeting of Stockholders will be held on Thursday, June 23, 2022, at 10:00 a.m. Pacific Time. This years meeting is a virtual stockholder meeting conducted exclusively via live audio webcast on the Internet at https://www.cstproxy.com/JasperTherapeutics/2022. As described in the proxy materials previously distributed, stockholders of record at the close of business on April 26, 2022 are entitled to participate and vote at the 2022 Annual Meeting. To participate, stockholders will need to enter the 12-digit control number included in the proxy materials delivered to such stockholders.

Information about the virtual meeting webcast and instructions for how stockholders can participate in the 2022 Annual Meeting are included in the definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2022 and are available on the InvestorsFinancials & Filings section of Jasper Therapeutics website at http://www.jaspertherapeutics.com or the website for the 2022 Annual Meeting at https://www.cstproxy.com/JasperTherapeutics/2022.

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing hematopoietic cell transplantation. It is designed to enable safer and more effective, and potentially curative, allogeneic hematopoietic cell transplants and gene therapies. A clinical study of JSP191 as a novel, disease-modifying, therapeutic for patients with lower risk MDS is also planned to begin in 2022. In parallel, Jasper Therapeutics, Inc. is advancing its preclinical mRNA hematopoietic stem cell grafts platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

Contacts:

John Mullaly (investors)LifeSci Advisors617-429-3548[emailprotected]

Jeet Mahal (investors)Jasper Therapeutics650-549-1403[emailprotected]

More:
Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022 - GuruFocus.com

Recommendation and review posted by Bethany Smith

MarketQuest.biz has announced the addition of new research titled Global Rheumatoid Arthritis Stem Cell Therapy Market from 2022 to 2028, which encompasses regional and global market data and is predicted to generate attractive valuation.The Rheumatoid Arthritis Stem Cell Therapy research covers market drivers, opportunities, limiting factors, and barriers. It provides a quantitative market study based on annual reports, product literature, industry announcements, and other sources.

The report explains the market definition, classifications, applications, engagements, and global Rheumatoid Arthritis Stem Cell Therapy industry trends are.It gives a realistic picture of the current market position incorporating original and predicted market estimates.The report gives a thorough analysis of their product portfolios to investigate the products and applications they focus on while working in the worldwide Rheumatoid Arthritis Stem Cell Therapy market. The report offers valuable suggestions to new just as set up players of the market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/121261

In order to improve industrial planning, data points such as flow patterns, openings, drivers, limits, and statistics are acquired from trusted sources. The data and numbers in the research report have been provided comprehensively, using graphical and pictorial representations to understand the market better.Further when datais synthesised, statistical analysis takes place. Several processes, including screening, integration, and data extrapolation, must be performed prior to data validation.

The product types covered in the report include:

The application types covered in the report include:

The countries covered in the market report are:

The key and emerging market players in the global market include:

ACCESS FULL REPORT: https://www.marketquest.biz/report/121261/global-rheumatoid-arthritis-stem-cell-therapy-market-2022-by-company-regions-type-and-application-forecast-to-2028

Significance of The Report gives the idea about thebroad and precise understanding, industry drivers and challenges affecting the industry growth, planning the business strategies and factors leading to the market development, and evaluating the market competition and planning

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on 1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: 1-201-465-4211Email: sales@marketquest.biz

More here:
Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -...

Recommendation and review posted by Bethany Smith

World Sickle Cell Day 2022:

Bangalore, June 16, 2022: There are as many as 2.5 million carrier of the gene (Hemoglobin AS) in India that can lead to sickle cell disease, with more than 1,25,000 actual patients spread across the country, with a much higher incidence in the tribal belt of the country. Sickle cell disease is associated with a significant risk of morbidity and premature mortality, especially among children. While in the west, a child receiving comprehensive care in high-resource settings has an estimated 99% survival into adulthood. However, in India, according to an ICMR study, about 20 per cent of children with sickle disease died by the age of two, and 30 per cent children with Sickle Cell Disease die before they reach adulthood.

Dr. Biju George, Professor & Head, Department of Haematology at CMC Vellore, People with Sickle Cell Disease, may beat a risk of progressive organ damage, impaired quality of life, considerable morbidity in childhood, and risk of premature mortality in adulthood [median survival of 58 years]. Sickle Cell disease patients who are undergoing regular life-long blood transfusions, have the best chance of survival and cure with a blood stem cell transplant. This transplant can come from a sibling or a family member. However, there is only a 30% chance of finding a matched sibling donor in the same family. The remaining 70% patients look for a matching donor through a stem cell registry or donor center- a database of voluntary donors between the age group of 18 to 50 years.

Dr. Govind Eriat Nair, Consultant Hematology Hemato-Oncology and Bone Marrow Transplant Gleneagles Global BGS Hospital, Bengaluru, If there is a fully HLA matched donor in the family, there is a 90-95% chance of cure with higher cure rates in younger children of below 12 years of age. However, due to underrepresentation of Indians in the global donor data pool, patients are unable to find a match on time. Also, the awareness about the disease is less, need of the hour is to raise the social awareness about this disease. Genetic counseling and newborn screening are the way forward. Effects of endogamy, consanguinity and role prenatal counseling needs to be addressed in primary screening.

DKMS BMST Foundation India is a non-profit organization dedicated to the fight against blood cancer and other blood disorders, such as thalassemia and sickle cell disease. The organization aims to give every blood disorder patient in need a second chance at life.

To mark World Sickle Cell Day, Patrick Paul, CEO, DKMS BMST Foundation India said, Sickle cell has variance and only the severe form needs a stem cell transplant. An early transplant can help patient with severe Sickle cell disease from organ damage. With rising cases in India, it is the need of the hour that stem cell transplants are made available to more patients to save lives. But due to the misconceptions and lack of awareness about blood stem cell donation, Indians are highly underrepresented in the global donor pool. This situation can only be changed by recruiting many more potential blood stem cell donors from the Indian ethnicity.

The success of a stem cell transplant depends of donors HLA (Human Leukocyte Antigen) matching the patient. The bodys immune system has proteins known as HLA to distinguish cells that belong to the body from those that do not. DKMS-BMST helps in unrelated donor transplant process which includes enrolling and counselling the donors, get their HLA typing done, facilitate search of the donors and later facilitate the blood stem cell collection and the transplant. So, far DKMS-BMST has registered over 60,000 potential donors and have helped 60 patients with second chance at life.

Register as a potential blood stem cell donor:

Healthy individuals between 18-50 years of age can register at: dkms-bmst.org/register

All it takes is five minutes of your time and a simple 3 step process:

Step 1: Visit the site, fill up an online form and you will receive a DIY swab kit at home.

Step 2: Once you receive the swab kit, fill out the consent form and take a tissue sample from the inside of your cheeks with 3 cotton swabs provided in the kit.

Step 3: Send back your swab sample in the pre-paid envelope provided.

DKMS laboratory will then analyze your tissue type and your details will be available in the global search for blood stem cell donors. If you do come up as a suitable donor, DKMS-BMST will get in touch with you straight away. Once you come up as a match, blood stem cells will be obtained from the bloodstream using a procedure called Peripheral Blood Stem Cell Collection, which is similar to a blood donation wherein only your stem cells are taken. This is a safe, non-surgical outpatient procedure.

Read more:
Stem Cell Transplant the only curative treatment for Sickle cell Disease - NewsPatrolling

Recommendation and review posted by Bethany Smith

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

MIRAMAR, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that Charles Arnold, Stemtechs Chairman and CEO, has received the Global Eagles Business Leader of the Year award.

The award was presented at a ceremony in Fort Lauderdale, Florida by Global Eagles International Chairman the Honorable Randy Avon. The Global Eagles is a group of diplomats, investment bankers, CEOs, University Presidents, investors and top international executives who gather regularly to network, present global projects to a group of seasoned peers, and to promote best leadership practices.

I am truly honored to receive the Global Eagles Business Leader of the Year award, said Chuck Arnold, Chairman and CEO of Stemtech. The Global Eagles community is a distinguished group that includes top leaders in business, the investment community, government and academia. The impact that this organization and its members have had on international development and infrastructure is hard to overstate. I continue to enjoy the camaraderie and friendship of fellow Global Eagles members, and I look forward to being a member for many years to come.

About Stemtech Corporation

Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent-protected in the U.S. and in select international markets. The Companys patented formulas help the release, circulation and migration of the bodys adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze (EMF Blocker). Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit http://www.stemtech.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed onMay 16th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

For Further Information, Contact:

Investor Relations: Frank J. Pena, 908-675-0581,

[emailprotected]

Read the original here:
STEMTECH CORPORATION CHAIRMAN AND CEO CHARLES ARNOLD RECEIVES GLOBAL EAGLES BUSINESS LEADER OF THE YEAR AWARD - StreetInsider.com

Recommendation and review posted by Bethany Smith

First Site Will Enroll First Patient in the Clinical Study

MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) BioRestorative Therapies, Inc. (the Company or BioRestorative) (NASDAQ: BRTX),a clinical stage company focused on stem cell-based therapies, today announced site initiation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Denver Spine and Pain Institute is the first clinical site to be initiated. Additional selected sites are expected to be initiated in 2022.

BioRestoratives Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Companys autologous investigational stem cell-based therapeutic, BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 centers in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.

Currently there are no approved, cell-based therapies for cLDD. While there is encouraging data that suggests that patients with cLDD could benefit from autologous stem cell transplants, the low oxygen micro-environment of the disc makes cell-based therapies challenging. BRTX-100 is manufactured under low oxygen conditions and engineered to survive this environment, said Scott Bainbridge, M.D., Principal Investigator for the BRTX-100 trial at The Denver Spine and Pain Institute. Positive proof-of-concept data in this trial could be disruptive and support the potential applicability of BRTX-100 to other spine and musculoskeletal disorders where low oxygen micro-environments are found.

We are pleased to initiate the first of several sites across the United States that will be enrolling for the trial, said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. Our sites have been carefully reviewed and selected and have clinical expertise in treating patients who could potentially benefit from BRTX-100. We look forward to working with the principal investigators and their clinical trial teams.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Companys latest Form 10-K filed with the Securities and Exchange Commission and other public filings. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email:ir@biorestorative.com

Read more:
BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) -...

Recommendation and review posted by Bethany Smith

For every procedure Hallie Barnard has undergone at MD Anderson, she receives a bead. The yellow ones symbolize each night in the hospital. The ones that glow in the dark represent radiology appointments.

Theyre for every poke, every wound cleaning, every physical therapy appointment, the 13-year-old said.

MD Anderson launched its Beads of Courage program in 2008 so young patients could document their journeys through cancer treatment. Collecting colorful strings of beads also provides some incentive to show up at dreaded doctor appointments.

Hallie has more than 350 feet of beads.

They symbolize everything that Ive gone through in the past four years, the Denton resident said.

Still, Hallie is less concerned about her own struggles through osteosarcoma, a cancer that begins in the bones, than she is with shining a light on the challenges other children face.

Every time I show people my beads, it dawns on them that children are going through so much, she said. And there are children with longer beads than I have.

According to the American Childhood Cancer Organization, about 15,780 children are diagnosed with cancer in the U.S. each year.

Their studies indicate 1 in 285 children will be diagnosed with cancer before their 20th birthday and that cancer is the leading cause of death for children between the ages of 4 and 14 in the country.

Children are dying of cancer at astonishing rates, Hallie said.

Regardless, she said, childhood cancer research is underfunded. Less than 4 percent of the federal budget for cancer research is dedicated to its study, according to the Childrens Cancer Research Fund, a national nonprofit.

I dont want any of my friends to die anymore, Hallie said. I want to show them that I am there for them. I am their voice. I can speak for those who cannot speak for themselves.

Hallies Heroes, the nonprofit she started with her parents, Elyse and Jesse Barnard, helps fund childrens cancer research.

But thats not how it began. The organization was founded to inspire individuals to register as bone marrow donors. Because, at the time, Hallie was facing another seemingly insurmountable challenge finding a match for herself.

Hallie was diagnosed with Diamond-Blackfan anemia when she was 13 months old.

Your bone marrow is basically what makes your red blood cells, she said. And with DBA, that fails to happen, Hallie said.

Elyse said her daughter did not seem to be growing normally or hitting milestones at the right time during her first year of life.

Our pediatrician would tell me everything was OK, she said. As a first-time mom, we tend to worry about everything, but I knew that something was wrong.

That fear was validated when Hallie went for her 12-month checkup. A blood test revealed low levels of hemoglobin, and she was admitted to the hospital.

Diagnostics pointed to Diamond-Blackfan anemia but doctors were still skeptical due to the rarity of the disease, Elyse said.

In the end, Hallie had a diagnosis. But treatment options were even more elusive.

Only five to seven babies per million have Diamond-Blackfan anemia, according to St. Judes Research Hospital.

Blood transfusions and steroids can be used to manage symptoms, but both take a toll on the body, Elyse said.

Stem cell transplants offer the only possible cure. The issue is finding a donor.

Theres just a 1 percent chance of finding a match for bone marrow transplants, Hallie said.

Her family began looking and moved from Virginia to Texas, after learning that Dallas had one of the four hospitals in the U.S. specializing in the disorder.

Out of the Barnards search for donors, Hallies Heroes was born.

In the search for her own bone marrow donor, other matches were made. So far, there have been 184 and the organization has inspired more than 8,000 people to join the bone marrow registry.

To its mission, Hallies Heroes added funding for Diamond-Blackfan anemia research and covering medical bills.

Hallie found her own match for a bone marrow transplant when she was 9. The procedure was scheduled the following year, 2018.

She was in the hospital for 60 days, kept in isolation for the duration to protect her fragile immune system, which was wiped out by chemo.

After 100 days, the bone marrow transplant is usually considered fully integrated, Elyse said.

You basically do a happy dance, because you have a new immune system, she said. We thought we were in the clear.

But at 120 days, Hallie had a new symptom.

I started getting horrible pains in my leg, she said. We found a small bump, the size of a mosquito bite.

The growth was right above her left knee. Doctors told her to draw a circle around it to see if it grew.

In a week, it had doubled, Hallie said.

Diagnostics revealed the bump was indeed a tumor.

In March 2019, Hallie was diagnosed with osteosarcoma, a bone cancer that develops most often in children and young adults.

Hallie was presented with a few different choices. She could opt for an amputation or limb salvage surgery to remove diseased bone and replace it with a metal implant or a bone graft, called at allograft, from another person.

We wanted to get a second opinion, Hallie said. Our doctor said, I studied under this amazing woman, Dr. Lewis. Yall should go to MD Anderson.

Dr. Valerae O. Lewis serves as the inaugural chair of orthopedic oncology at the hospital. In fact, she created the Department of Orthopedic Oncology in 2014.

The Barnards made an appointment to see her in mid-April 2019.

Data from MD Anderson shows that between 800 and 900 cases of osteosarcoma are diagnosed annually in the U.S. About half of these are children and teens.

Lewis presented Hallie with three options. You can do an amputation, she began.

Historically, that was the only choice available to remove the tumor completely. But now there are additional options limb-salvaging surgery and rotationplasty, Lewis said.

Limb-salvaging surgery can be performed if the cancer has not metastasized.

Limb-salvage is a great option, because it gives kids the ability to keep their legs, Lewis said. But it does take a toll.

Patients activity levels are restricted and additional operations are needed down the road, probably every 15 to 20 years.

The third option, a rotationplasty, removes the tumor along with the middle part of the leg and the knee. The surgeon then rotates the lower leg 180 degrees before reattaching it to the thigh.

Its like an amputation, but we create a new knee, Lewis said.

Rotationplasty allows patients to be higher functioning. Its easier to walk, Lewis said. You can bike, skate and swim. Everything you need a knee for, you can do.

Hallie chose rotationplasty. Surgery was scheduled for late June 2019, and she had chemo before and after surgery.

She was 11 at the time and had complications while healing, including infections. She needed a wound vacuum for about 11 months. When Hallie finished chemo in 2020 in Fort Worth, her bones had not yet fused.

Then, Dr. Lewis came up with a genius idea, Hallie said.

Lewis inserted a titanium rod into the nonhealing site to help.

Hallie said that Lewis restored her confidence.

Theres a point when a patient gives up. And theres also a point when a doctor gives up. She said that she had not given up on my leg yet, Hallie recalled.

After rotationplasty, a prosthesis is worn, and patients have to relearn how to walk.

Even though the ankle now functions as the knee, it is entirely different from the typical configuration, Lewis said.

The foot fits into the prosthesis, she said. And one needs to remember that it is a functional foot interfacing with the prosthesis.

The toes can provide balance and aid in powering the prosthesis, Lewis added. The plantar surface also allows for bearing weight.

Hallie was at MD Anderson for about seven months, working on both physical and occupational therapy, until she headed back to Denton April 8.

Hallie has progressed nicely and is walking distances without support, Lewis said.

With further physical therapy and continued dedication she anticipates Hallie will be running, skipping and jumping in the future.

Hallies follow-up appointments at MD Anderson are scheduled every three months.

When Hallie was first diagnosed with osteosarcoma, she remembers telling her mother, God put me back in the hospital to help other children.

Now she advocates for both children with cancer and those with Diamond-Blackfan anemia.

At one point, while Hallie was healing from surgery, Elyse and Jesse went to a wall where donors names are displayed on the ninth floor of MD Anderson.

Every day, her dad and I passed the wall, Elsye said. One day, she wanted to see Hallie added to the names.

After changing the bylaws of the nonprofit, Hallies Heroes pledged $50,000 over five years in support of Lewis research in the area of pediatric sarcoma.

Hallie went on the wall in November.

It was really cool to come full circle with that, Elyse said. We were once there as parents, not knowing if our child would survive and seeing all the people donate money so that she could.

Now were giving back, because we want other children to survive, she added.

The funding will make a significant impact, Lewis said, and will go toward researching treatments for pediatric sarcoma.

Hallie is a success story, Lewis said. She is our ambassador and is a cheerleader to other patients. She wants to give back and help other kids like her.

Peyton is a Houston-based freelance writer.

Read the original post:
Surgery gives teen opportunity to help other kids with cancer - Houston Chronicle

Recommendation and review posted by Bethany Smith

Anadrole Reviews Does CrazyBulks Anadrole (Anadrol) Supplement Really Work? Do the ingredients have any negative side effects? Read its price, results, dosage & customer reviews!

Official Website: Click Here

What is Anadrole?

Anadrole is a muscle-building supplement developed by CrazyBulk that imitates the effects of the anabolic steroid Anadrol and androgen oxymetholone, which treat low levels of red blood cells.

Its primary function is to stimulate the synthesis of red blood cells in your body, which in turn helps to reduce the symptoms of anemia, including lethargy, muscle weakness, and weariness, among other symptoms.

Anadrole from CrazyBulk contains high concentrations of various proteins, amino acids, and ergogenic herbs.

These ingredients all work together to produce the same results as oxymetholone without harming your health.

It is designed to offer all of the advantages that its equivalent, available only by prescription, does, but without any potentially harmful effects.

Because the steroid Anadrol increases your stamina and assists you in fighting exhaustion, the Anadrole supplement makes it possible for you to attain bigger improvements in muscle mass.

It can effectively assist in growing muscle and bolstering muscle strength, and it speeds up the healing of muscles after exercise.

Your workouts will be more effective if you include them in your routine, and it is simple to use Anadrole in any fitness program.

Improve your physical performance, maintain your muscle mass, and shed excess weight with the help of this cutting-edge muscle-building supplement Anadrole.

It provides sustained energy surges, enabling you to work better and for longer at the gym. As a result, you can break through muscle-building plateaus more easily.

You will be able to achieve your fitness objectives more quickly and easily if you consistently apply this powerful method.

Click to Learn More About the Anadrole on the Official Website

How does Anadrole supplement work?

It accomplishes this by utilizing two metabolic processes stimulated by its proprietary formulas. To begin, taking this Anadrole can enhance a process known as erythropoiesis, which takes place in the bone marrow.

To put it another way, the stimulatory impact that the capsules have on the bone marrow stem cells causes an increase in the creation of red blood cells.

Because of this increased RBC, more oxygen will be carried into organs, particularly the muscles.

As a consequence, the muscles may be able to recover from weariness more quickly.

The second impact is known as the androgenic effect, which plays a role in both the manufacture of testosterone and the improvement of the bioavailability of male hormones.

Testosterone plays a significant role in the initiation of fat burning, which is beneficial to the process of creating lean muscle.

Click to Learn More About the Anadrole Supplement

Benefits of consuming Anadrole Capsules:

The Anadrole supplement sold by CrazyBulk is comprised of a potent composition that helps maintain your muscle health in a variety of ways.

Shocking New Anadrole Report: This May Change Your Mind

What are the Ingredients used in Anadrole Supplement?

Anadrole has appropriate quantities of natural substances that improve muscle strength, growth, and recovery and is packed full of these nutrients.

They cooperate to alleviate the symptoms associated with iron deficiency and low numbers of red blood cells.

In light of scientific research, the following is everything you need to know about the components that are found in Anadrole and the benefits that come from them:

Tribulus Terrestris, a plant native to the Mediterranean region that bears fruit and is a member of the caltrop family, is traditionally employed in herbal medicine as an aphrodisiac.

It is loaded with compounds that improve sexual performance in both men and women and has these substances in plenty.

The compounds found in the fruit of the Tribulus Terrestris plant have the power to interfere with the function of particular hormones in your body beneficially, which results in the production of ergogenic effects.

Anadrole from CrazyBulk has a total of 500 mg of Tribulus Terrestris fruit extract packed into every serving.

Soy protein is a type of protein that can be acquired from soybeans. It is unique in that it contains all of the essential amino acids your body cannot produce independently.

Because it is a complete protein, it stimulates muscle protein synthesis in your body by supplying your body with significant quantities of all of the required amino acids.

Losing weight, maintaining good cholesterol levels, and gaining muscle are all benefits. The Anadrole sold by CrazyBulk includes 200 mg of soy protein extract in every serving.

Whey protein, the primary protein found in dairy products, encourages the development of new proteins within your body by providing it with all of the needed amino acids.

It is a protein that is broken down very quickly and is an essential component in the process of creating new muscle protein.

Anadrole sold by CrazyBulk comes with 200 milligrams of whey protein concentrate in every single serving.

Nitric oxide can be produced from the amino acid L-arginine when it is metabolized in the body.

L-arginine has a role in maintaining healthy blood flow by contributing to the production of nitric oxide, which is important for keeping your blood vessels relaxed.

In addition, it influences particular hormones in your body, such as insulin and growth hormone, amongst others.

L-carnitine is a naturally occurring amino acid derivative that aids in synthesizing energy and enhances thermogenesis and encourages body fat reduction.

Your endurance will improve due to acetyl-l-role carnitine in the mitochondria, and you will be able to push yourself further during your workouts.

Acetyl l-carnitine is the primary factor responsible for Anadroles capacity to increase ones energy levels. Anadrole sold by CrazyBulk contains 50 mg of acetyl l-carnitine in every serving.

Shocking Results of This Anadrole Supplement Reported!

Pros of Anadrole:

Cons of Anadrole:

Check Out Anadrole Supplement Reviews From Real-Life Customers

Side effects of Anadrole Crazy Bulk

Anadrole does not contain an API, which stands for active pharmaceutical ingredient, or, to put it another way, the chemical compound responsible for carrying out all of the necessary functions.

The so-called beneficial effects are caused by certain herbs and the extracts of those herbs, similar to the way that Ayurvedic medications and other traditional treatments function.

Because you are genuinely consuming certain plant components in capsule form, there are no adverse consequences, unlike those caused by steroids, such as kidney failure, liver damage, high blood pressure, or organ damage.

Click to Order Anadrole Steroids From the Official Website (60 Days Money-Back Guarantee)

Pricing of Anadrole and Return Policy

One bottle of CrazyBulks Anadrole costs $64.99 and includes 60 individual capsules in each bottle.

If you buy two bottles at once, you will receive a free bottle as a bonus, and the total cost of 3 bottles is $129.98.

When you place an order straight through the official CrazyBulks Anadrole supplement website, you get free shipping on all of your purchases, no matter where you are.

Check Current Anadrole Supplement Pricing & Discounts!!

How to use Anadrole?

To experience the maximum potential of Anadrole, the manufacturer suggests taking two capsules each day for at least two months.

Because it requires the body a little bit more time to digest it, it is recommended that the Anadrole be taken first thing in the morning.

It is recommended that you take both capsules at the same time, at least twenty minutes before breakfast, to ensure that the Anadrole capsules are adequately absorbed along with the food.

When taking capsules, it is advisable to consume them with water or fruit juice; alcohol of any kind should be avoided at all costs.

The body is better able to properly distribute the tablets contents when it is given for 60 days consecutively followed by 10 days off cycle.

Click to Get the Best Deal on Anadrole from the Official Website

Anadrole Reviews Final Verdict

Anadrole is a great option for beginners and intermediates looking for a supplement that will help them gain muscle, increase their endurance and stamina, and improve their lean body mass.

This one, in contrast to other legal steroids, has a price tag that is slightly more reasonable, and its impact is comparable to that of the original steroid.

This products capacity to increase RBC counts assists in the fight against fatigue and shortens the time needed for recovery after exercise.

As a result of the herbal formulation, Crazy Bulk products do not cause any unfavorable health effects and do not cause any side effects.

Get Anadrole Now With Special Discount (Worldwide)!

Disclaimer: We are a professional product review website. We might receive compensation when you buy through our website, we may earn a small affiliate commission. The information contained on this website is provided for informational purposes only and is not meant to substitute for the advice provided by your doctor or other healthcare professional. The products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

People also search for: anadrole reviews anadrole review anadrole crazy bulk review anadrole side effects anadrole crazy bulk anadrole vs anadrol anadrole crazy bulk side effects anadrole results anadrole ingredients

Continued here:
Anadrole Reviews - Best Alternative to Anadrol Steroid? Any Side Effects? - MarylandReporter.com - MarylandReporter.com

Recommendation and review posted by Bethany Smith

Amrita Hospitals announced on Thursday that its new 2,400-bed campus will soon be open to the public in Faridabad in August this year. During the press conference on Thursday, hospital management announced that the new Amrita Hospital is spread across 133 acres of land in Faridabad and it will be the biggest private sector hospital in India.

This would be the second large-scale Amrita Hospital in India after the iconic 1,200-bed Amrita Hospital in Kochi, Kerala, which was established 25 years ago by the Mata Amritanandamayi Math.

The new hospital is located at Sector 88, Faridabad and it will have a total built-up area of 1 crore sq. ft., including a 14-floor-high tower that will encompass the key medical facilities and patient areas. During the press conference, Swami Nijamritananda Puri, Head, Mata Amritanandamayi Math, Delhi announced that the 81 specialties at the hospital will include eight centers of excellence, such as oncology, cardiac sciences, neurosciences, gastro-sciences, renal sciences, bone diseases and trauma, transplants, and mother and child.

The hospital will become operational in stages, with 500 beds opening in August this year. In two years, this number will rise to 750 beds, and further to 1,000 beds in five years. When fully operational, the hospital will have a staff of 10,000 people, including over 800 doctors.

On how the new hospital has incorporated the aspects of pandemic-induced demands, Dr. Sanjeev K Singh, Medical Director, Amrita Hospital, Faridabad told Financial Express.com: We have learned a lot from the pandemic. The construction of the hospital began 5-6 years ago and the learnings from the pandemic also got incorporated along the way. For example, any patient who comes in an emergency gets facilitated in a 40-bed setup. In that set-up, we have a decontaminated area in which anyone who needs to shower will be sent there. We have four negative pressure rooms and if we have any suspected cases of covid or covid-like diseases we can send them to concerned specialists. The mechanism of shifting is also planned and implemented. In all critical care units, there are positive pressure isolation rooms.

The massive facility will also include 534 critical care beds which is the highest in India, the hospital management claims. The hospital campus will also include 64 modular operation theaters, most advanced imaging services, fully automated robotic laboratory, high-precision radiation oncology, most updated nuclear medicine, and state-of-the-art 9 cardiac and interventional cath lab for clinical services. Cutting-edge medical research will be a strong thrust area, with a dedicated research block spread across a 7-floor building totaling 3 lakh sq. ft with exclusive Grade A to D GMP lab with focus on identifying newer diagnostic markers, AI, ML, Bioinformatics etc.

Dr. Singh also told Financial Express.com that they want to integrate all aspects of medical science and bridge the gap between clinicians and scientists.

In Kochi, we have established tissue engineering, a nano-medicine-based cardiac stent, bone growth, and lots more. What we are looking at Faridabad campus is developing something new in stem-cell therapies. We want to create techniques like creating human cells on our own in our GMP labs as generally, we rely on international counterparts for such procedures. Recently, we conducted research in which we found that we can use patient pluripetin stem cells in tumours and it will destroy them. For us, oncology is the big thrust area but other areas will be a focus too. The intent of our research facility will be to make the high-end expensive equipment and treatments cost-effective for the common man. We want to integrate medicine, engineering, biotechnology, and other segments altogether, Dr. Singh told Financial Express.com.

Dr. Singh also said that they have already been awarded the Advanced ICMR Clinical Trial Unit and this will enable them to conduct their trials in the new facility.

Mata Amritanandamayi has allocated a certain amount of seed money to initiate research. On the basis of submitted proposals, things will materialise and start, he added.

Dr. Singh also told Financial Express.com that the new hospital will also be empaneled. There is a process of 3-6 months and then after medical facilities will be available under all panels like ECHS, CGHS and other TPAs, he added.

During the press conference, Dr Singh also informed that the hospital will be among the very few facilities in the country to conduct hand transplants, a specialty pioneered by Amrita Hospital in Kochi. We will also do transplants of liver, kidney, trachea, vocal cords, intestine, heart, lung, pancreas, skin, bone, face and bone marrow, he said.

Training of medical students and doctors will be a strong focus area. The hospital will have state-of-the-art robotics, haptic, surgical-medical simulation centre spread across 4 floors and 1.5 lakh sq. ft area, the biggest such learning & development facility for doctors in the country. The facility will also host a medical college and the countrys biggest allied health sciences campus, he stated.

Moreover, the management also informed that ultra-modern Amrita Hospital at Faridabad would be one of Indias largest green-building healthcare projects with a low carbon footprint. It is an end-to-end paperless facility, with zero waste discharge.

There is also a helipad on the campus for swift transport of patients and a 498-room guest house where attendants accompanying the patients can stay, they said.

Read the original post:
New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital - The...

Recommendation and review posted by Bethany Smith

According to the American Academy of Dermatology Association, it's normal to shed between 50 to 100 hairs daily. However, if you're experiencing more hair loss on a regularly, other factors could be the cause. Hair loss can result of genetics, medical conditions, stress and vitamin deficiencies.

Diet plays a crucial role in developing healthy hair. If you severely lack essential nutrients such as vitamin A, C, D, E, zinc, protein, fatty acids and Biotin, it can lead to hair loss.

With a proper diet, you could have thicker, healthier hair. Keep reading to find out what vitamins are the best for hair growth.

Read more:Best Vitamins for Hair Growth

Vitamins do many amazing things for hair: They can aid in cell growth, prevent free radicals from damaging it, keep it from graying prematurely and nourish the follicles that stimulate growth.

Here are the best vitamins for hair growth and thickness.

Biotin, also known as vitamin B7, stimulates the production of keratin to increase follicle growth. Biotin deficiencies tend to be rare, with those diagnosed with Biotinidase Deficiency being the most common. You can find this vitamin in many foods, including eggs, meat, fish, nuts, eggs, sweet potatoes and seeds.

The recommended intake is 30 micrograms for adults daily.

Hair cells are the fastest-growing part of the body. It makes sense, then, that vitamin A is the perfect fuel for that growth. When your body absorbs vitamin A, it produces sebum. That's an oily substance that moisturizes your scalp, keeping it and your hair follicles healthy. Having a vitamin A deficiency could result in you experiencing hair loss.

If you're looking to consume more vitamin A, you'll want to consume foods high in beta-carotene, which turns into vitamin A. Foods high in beta-carotene include sweet potatoes, pumpkin, carrots, spinach and kale. You can also find it in cod liver oil, eggs, yogurt and milk.

The recommended daily intake for vitamin A is up to 900 mcg for men and 700 mcg for women.

Oxidative stress is one of the main factors contributing to hair loss. This occurs when we have an imbalance of free radicals and antioxidants in our bodies which can lead to an electron imbalance that could result in hair loss.

The solution is to consume foods with vitamin C. Your body possesses antioxidants that curtail free radicals' hair damage by balancing their electrons when you do. Along with balancing the scales, Vitamin C aids your body in producing collagen (prevents hair from graying prematurely) and absorbing iron which can help hair grow. Smoking, drinking alcohol and having a poor diet can lead to a vitamin C deficiency.

You'll find vitamin C in citrus fruits, peppers, strawberries, tomatoes and guavas. Since your body doesn't produce it, you'll need to include these in your diet or have a supplement with vitamin C.

Daily intake for vitamin C is up to 90 milligrams per day for adult men and 75 milligrams for adult women. Taking too much Vitamin C could result in heartburn, muscle cramps, fatigue, skin flushing and possible kidney stones.

Read more: Best Multivitamins

Vitamin D deficiencies can lead to hair loss conditions like alopecia, female pattern hair loss and excessive shedding. You'll find these depletions more in people aged 65 and over.

To get more vitamin D intake, you can incorporate fatty fish, cod liver oil, fortified foods (cereal, eggs, bread, yogurt) and mushrooms into your diet. Alternatively, you can catch some midday sun rays.

600 IU of vitamin D is the recommended dosage for adults. Taking too much vitamin D could result in nausea, weight loss, disorientation, and heart rhythm issues.

Vitamin E contains the same antioxidant prowess as its vitamin C counterpart possesses. It means it can curb oxidative stress by balancing out the electron level in free radicals. People more susceptible to vitamin E deficiencies include those with health conditions such as Crohn's or cystic fibrosis.

Vitamin E is an effective method for treating hair loss. A small study revealed that people taking vitamin E supplements for eight months experienced a 34.5% increase in hair growth. You can also find vitamin E in sunflower seeds, spinach, avocados, and almonds.

If you plan to go the supplemental route, the recommended dietary allowance is 15 milligrams daily.

Read more: Best Food Sources of Every Vitamin and Mineral You Need

Iron fuels the production of hemoglobin, a protein found in your body's red blood cells. These cells distribute oxygen to cells throughout your body, aiding in their repair and growth. An iron deficiency can lead to hair loss, with women being the most susceptible.

You'll find iron in foods like eggs, red meat, lentils, spinach, oysters and clams. If your doctor recommends it, you can take an iron supplement.

The recommended daily iron intake is 45 mg. Keep in mind that taking too much iron could result in constipation, stomach pain, and vomiting.

Zinc promotes hair growth and keeps the oil glands surrounding the follicles working well. If you have a Zinc deficiency, you could experience hair loss. Those most susceptible to zinc deficiencies are those who drink alcohol excessively, people with Crohn's, pregnant or breastfeeding women and those with chronic kidney ailments.

You can find zinc in many common foods like beef, spinach, wheat germ, pumpkin seeds, oysters and lentils. The recommended daily dosage of iron is 11 mg for men and 8 mg for women. Taking too much could result in loss of appetite, cramps and headaches. It can also lower your good cholesterol.

Read more: Best Vitamins for Hair, Skin and Nails

Hair supplements are not overnight solutions. It may take months before you'll notice small improvements. Remember that the success rate depends on the cause of the hair loss, your diet, genetics and other factors.

Vitamins can restore damaged hair, prevent it from aging prematurely, reduce hair loss, and improve growth and volume. However, they're not a one-size-fits-all solution. You'll want to consult your doctor if your hair loss stems from stressful environments, underlying medical conditions or genetics, as they can create a targeted treatment plan that might include vitamins.

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

Visit link:
Take These 7 Vitamins if You Want Longer, Thicker Hair - CNET

Recommendation and review posted by Bethany Smith

Should there be laws in place to protect people with obesity from being denied a job or housing opportunities on the basis of their weight status? Whether or not you answer yes to that question may be influenced by your gender, race, or your own weight, according to a study that examined how these factors impact perceptions of obesity, weight bias, and weight-based discrimination laws.

About half of Americans would support laws against weight-based discrimination, with those who have personally experienced weight bias being about twice as likely to support the policy as people who have not, according to thefindings, which were presented June 7 at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS)in Dallas.

Weight bias is defined as negative attitudes, beliefs, judgments, stereotypes, and discriminatory acts aimed at people simply because of their weight, according to Obesity Action Coalition (OAC). This can be obvious or subtle, and can happen in any setting work, healthcare, school, and even personal relationships.

What exactly does weight bias look like in practice? Take the case of Taylor v. Burlington Northern Railroad Holdings, Inc. Casey Taylor was an ex-Marine who sued after the railway company made a conditional job offer but then revoked it when a medical exam found his BMI (body mass index) to be in the severely obese range. Taylor was 5 feet 6 inches tall and 256 pounds, which translates to a 41.3 BMI.

A person with a BMI of 25 to 29.9 is considered overweight, and a person with a BMI of over 30 is considered obese. According to the National Heart, Lung, and Blood Institute,BMI is calculated on the basis of a persons weight and height, and the same formula is used for both men and women.

The railway company informed Taylor that it was their policy to not hire anyone who had a BMI over 35; to be able to start work for the railroad, he would need to provide proof of satisfactory health by undergoing several tests (that he would have to pay for out of his own pocket) including a sleep study and an exercise tolerance test, or lose 10 percent of his body weight and keep it off for six months.

Taylor claimed this was a violation of Washington state's Law Against Discrimination. The case made it all the way to the Washington Supreme Court, where the court ruled in favor of Taylor. The court held that obesity is an impairment, and therefore a protected disability.

But statutes like the one in Washington are few and far between, says the senior author of the research,Fatima Cody Stanford, MD, MPH, an associate professor andobesity medicine physician scientist at Massachusetts General Hospital and Harvard Medical School in Boston. There are no universal laws in the U.S. for weight discrimination. With the exception of Washington and Michigan and a few cities, it is legal to discriminate on the basis of weight, she says.

To find out more about peoples perceptions about obesity bias, researchers had a diverse group of 1,888 adults complete a 26-item online questionnaire; the participant makeup was as follows: 328 Asian or Pacific Islander, 404 Hispanic or Latinx, 395 Black, and 761 white. Questions explored issues such as whether or not obesity is a disease, what most Americans think about obesity, awareness of obesity advocacy organizations, and whether or not the participant supported laws against weight discrimination.

About half of Americans overall would back such legislation, and the researchers found there were several major predictors of support or lack thereof. Controlling for other variables, if you personally experienced weight bias, you were twice as likely to support this policy. If you considered obesity to be a disease, you were 1.8 times as likely, says Matt Townsend, MD, the lead author and a resident internal medicine doctor at Duke Health in Durham, North Carolina.

Interestingly, Black race and female gender were each associated with being 1.4 times as likely to support antidiscrimination laws. We can only conjecture that lived experience of stigma is a powerful motivator to make things more equitable, he says.

It makes sense that individuals who have had to navigate race and gender bias are more likely to support laws around weight bias, says Dr. Stanford. These individuals probably face more weight-based discrimination just because of their intersectional identities of being part of a racial/ethnic group, being female, and then having the disease of obesity compounding that, she says.

The American Medical Association (AMA) designated obesity a disease in 2013. Although it is influenced by behavioral factors, experts now recognize that genetics, environment, social determinants of health, and biological factors influenced by medications, illnesses, and hormones all play a role.

Having too much body weight for your height is associated with an increased risk of heart disease, high blood pressure, type 2 diabetes, and even certain cancers. Its estimated that more than two in three U.S. adults have overweight or obesity, according to theU.S. Department of Health and Human Services.

When people have excess weight, other people make many assumptions. They may assume those individuals are lazy, passive, lack self-control, or make poor decisions, says Stanford. We know these biases are not true, but they are widely held beliefs in our society, she says.

Dr. Townsend believes that a problem as culturally ingrained as weight bias needs to be addressed on multiple fronts individual, institutional, and through societal or policy means. At a personal level, it's more awareness on the issue how it creates disparities in attainment, socioeconomic status, and psychological harms, he says.

At the institutional level, organizations can take steps to root out the most common sources of weight stigma, says Townsend. Our study found that the media was the most frequent source of weight bias, but high rates were also experienced in the employment and healthcare sectors, he says. Townsend uses the entertainment industry as an example of how a bias could be recognized and corrected by avoiding the fat-lazy stereotype in movie characters.

Action is also needed at the policy level, he says. The Civil Rights Act of 1964 does not identify weight as a protected condition, and as Stanford notes, laws that prevent weight-based discrimination are the exception, not the rule.

Legislation has the potential to create more equitable protection for people with obesity, and our study showed about half of Americans were supportive of the idea of laws against weight discrimination, says Townsend. These findings could be used to build public support in these natural allies for antidiscrimination legislation, he adds.

Wondering if you have negative assumptions around weight and may be part of the problem? One way to find out is to take the free Harvard implicit association test about weight bias, says Stanford. This can help you discern where you are on the spectrum; if you have biases in this area, then you can begin work on improving that."

Educating yourself can be a good start, she says. The Obesity Action Coalition offers information and resources to help people understand the issue, as well as ways that people can take action to foster positive change.

See the original post here:
Half of Americans Support Laws Against Weight-Based Discrimination - Everyday Health

Recommendation and review posted by Bethany Smith

California (United States) The Female Technology (Femtech) Market research report provides all the information related to the industry. It gives the outlook of the market by giving authentic data to its client which helps to make essential decisions. It gives an overview of the market which includes its definition, applications and developments and manufacturing technology. This Female Technology (Femtech) market research report tracks all the recent developments and innovations in the market. It gives the data regarding the obstacles while establishing the business and guides to overcome the upcoming challenges and obstacles.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample-request/280457

Competitive landscape:

This Female Technology (Femtech) research report throws light on the major market players thriving in the market; it tracks their business strategies, financial status and upcoming products.

Some of the Top companies Influencing in this Market include:ALYK, Inc., Aytu BioScience, Inc., Biowink GmbH, Bloomlife, CORA, Flo Health, Inc., Glow, Inc., Inne, Kasha, NaturalCycles Nordic AB, Ovia Health, Plackal Tech, Sustain Natural, The Flex Company, Thinx, Inc., Celmatix Inc., Conceivable Inc., Lia Diagnostics Inc., Lucina Health, Inc., Progny, Inc., Univfy Inc.

Market Scenario:

Firstly, this Female Technology (Femtech) research report introduces the market by providing the overview which includes definition, applications, product launches, developments, challenges and regions. The market is forecasted to reveal strong development by driven consumption in various markets. An analysis of the current market designs and other basic characteristic is provided in theFemale Technology (Femtech) report.

Regional Coverage:

The region wise coverage of the market is mentioned in the report, mainly focusing on the regions:

Get Up to 30% Discount on the first purchase of this report @:

https://www.a2zmarketresearch.com/discount/280457

An assessment of the market attractiveness with regard to the competition that new players and products are likely to present to older ones has been provided in the publication. The research report also mentions the innovations, new developments, marketing strategies, branding techniques, and products of the key participants present in the global Female Technology (Femtech) market. To present a clear vision of the market the competitive landscape has been thoroughly analyzed utilizing the value chain analysis. The opportunities and threats present in the future for the key market players have also been emphasized in the publication.

This report aims to provide:

Table of Contents

Global Female Technology (Femtech) Market Research Report 2022 2029

Chapter 1 Female Technology (Femtech) Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Female Technology (Femtech) Market Forecast

Buy Exclusive Report @: https://www.a2zmarketresearch.com/checkout

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

See the original post:
Female Technology (Femtech) Market to Witness Huge Growth by 2029 |Abcam plc, Active Motif, Inc. Indian Defence News - Indian Defence News

Recommendation and review posted by Bethany Smith

WASHINGTON--(BUSINESS WIRE)--The Womens Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and Altoida, a precision neurology company pioneering non-invasive brain health diagnostics using AI and augmented reality (AR), today announced results from a study showing sex-based differences using digital biomarker data collected from Altoidas digital cognitive assessment platform.

Published in EPMA Journal, the study explored sex differences in Altoidas digital cognitive assessment platform in a sample of 568 subjects consisting of a clinical dataset (mild cognitive impairment and dementia due to Alzheimers Disease) and a healthy population. The study results found that a biological sex classifier built on digital biomarker features, captured using Altoidas application, achieved a 75% performance rate in predicting biological sex in healthy individuals, indicating significant differences in neurocognitive performance signatures between males and females.

The discernible differences seem to decline in subjects with mild cognitive impairment (MCI) or overt Alzheimers Disease (AD), independent of age. In the healthy population, the primary differentiating features are micro hand gestures detectable on a wearable, that measured accelerometric data. In this assessment domain, the accuracy reached 80 percent versus the overall neurocognitive Altoida performance. The study found that sex differences can be observed via digital biomarkers, which has the potential to impact diagnosis and treatment of AD.

Our research shows how digital biomarkers can detect sex-based differences which are often overlooked when using standardized cognitive neuropsychological assessment, said Antonella Santuccione Chadha, M.D., CEO and Co-Founder Women's Brain Project and Chief Medical Officer at Altoida. These findings support the need for researchers and drug developers to account for sex-based characteristics in investigating prospective treatments for Alzheimers Disease.

Our ultimate goal is to build an integrated framework for sex-based cognitive assessment to predict, monitor and provide precision treatment of neurodegenerative disease, said Travis Bond, CEO, Altoida. Such a framework could be used for early detection of the disease, and enables both targeted prevention strategies and personalized Alzheimers treatment for patients. By integrating sex with risk stratification based on genetics and individual risk factors with the use of digital biomarker monitoring applications, this will enable the early detection and treatment of symptoms, when a patient has MCI, before development into Alzheimers.

Study results highlight sex-based differences

An MCI diagnosis is determined often later in females, compared to males. This study suggests that using sex-adjusted tools for diagnosis (or sex-adjusted cut-offs) may be needed to improve diagnostic precision. Predictive diagnostics using AD biomarkers in the pre-symptomatic or oligosymptomatic (MCI) stage, followed by targeted preventions and treatment personalized to those individuals considered high risk, are increasingly considered to represent the best chance at successful AD management.

The performance dropped when this classifier was applied to more advanced stages on the AD continuum, including MCI and dementia, suggesting that sex differences might be disease-stage dependent. The results indicate that neurocognitive performance signatures built on data from digital biomarker features are different between men and women. These results stress the need to integrate traditional approaches to dementia research with digital biomarker technologies and personalized medicine perspectives to achieve more precise predictive diagnostics, targeted prevention, and customized treatment of cognitive decline.

The results may also enable researchers to better understand the pathophysiological mechanisms of the disease, which might differ between sexes, with opportunities for personalized treatment. From a predictive medicine perspective, including sex differences might make predictions more precise, especially with algorithms that incorporate multiple variables. In particular, considering sex differences may improve the ability to predict fast decliners in MCI patients, which is a key element for planning therapy and care options. From a precision medicine perspective, whether a patient is a male or female makes a difference, based on the study data. More data on sex differences could guide future clinical practice, informing choices for ad-hoc prevention, diagnosis and treatment options.

These findings should be integrated with the most powerful recent developments in digital medicine to build models of disease development that can fully integrate the effect of sex, digital biomarker technology being one of the most promising tools when developing drugs or digital therapeutics in AD. The study was conducted to show the research community that there are potential sex differences in cognitive testing in Alzheimers, in order to implement measures to mitigate potential biases in clinical application.

Go here to read the rest:
Women's Brain Project and Altoida Announce Results Highlighting Sex-Based Differences Using Predictive Digital Biomarker in Alzheimer's Disease -...

Recommendation and review posted by Bethany Smith